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Previous work has shown that photoactivation of lipophilic agent merocyanine 540 
generates a mixture of photoproducts (pMC540) that selectively induce cell death in 
human leukemia, lymphoma, and a variety of other tumor cell types in vitro and in vivo 
(Gulliya et al., 1994; Pervaiz et al., 1998). Earlier work has also shown that the 
photoproduct C1 causes activation of caspases, drop in transmembrane potential and 
release of cytochrome c from the mitochondria (Pervaiz et al., 1999). However, the signal 
transduction pathway that leads to cell death has not been elucidated. As drugs may cause 
multiple effectors to come into play, it is essential to characterize the different 
transcription factors and pathways they induce for a comprehensive account of the 
mechanism of drug action. The present study was designed to decipher the mechanism of 
C1 mediated cell death. A high throughput method was used and a microarray analysis 
was performed to study the effect of drug C1 at various time points upon HL60 cells (a 
human promyelocytic leukemia cell line). The analysis showed that a large number of 
transcripts are upregulated in the early time points (table1) including the orphan nuclear 
receptor NR4A3. This study has validated here by real time PCR the upregulation of the 
orphan nuclear receptor NR4A3, and also NR4A1 which is a member of the same family 
of receptors. This study characterizes the role of nuclear receptors NR4A1 and NR4A3 in 
drug C1 mediated apoptosis and has identified the functional relevance of the increase in 
the transcript level of NR4A1 and NR4A3. 
This thesis shows here that in MCF-7 breast cancer cells, silencing NR4A3 has an impact 
on its reponse to low dose drug treatment – silencing NR4A3 leads to attenuated response 
to drug C1. It also finds that silencing NR4A1 leads to an even greater effect of 
attenuation of cell death. The results thus point to the importance of NR4A1 and NR4A3 
in drug mediated apoptosis.  
Results from this work also propose a mechanism of NR4A3 action – our observation 
that silencing NR4A3 leads to a decrease in the levels of VDAC1 (a major outer 
mitochondrial membrane protein) in the mitochondrial enriched fraction indicates that 
NR4A3’s effect on drug mediated apoptosis may involve signal transduction through 
VDAC1 - which has been implicated with a role in apoptosis (Elinder et al., 2005; Liu et 
al., 2006; Zaid et al., 2005). We find that the decrease in VDAC1 protein levels in the 
mitochondria upon NR4A3 silencing corresponds to abrogation of apoptosis, but only 
when the drug dosage is low. At higher doses of the drug the silencing of NR4A3 and the 
subsequent lowering of VDAC1 levels in mitochondria do not protect from cell death 
possibly because the overwhelming response from other signal transduction pathways 
render VDAC1 levels inconsequential. Our findings suggest that in MCF-7 cells triggered 
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1.   ONCOGENESIS AND THE DEVELOPMENT OF CANCER THERAPIES 
 
Cancer is the result of multiple genetic alterations and it has long been known that a 
single mutation is insufficient for the development of malignancy. Tumors evolve by 
acquiring capabilities to overcome a multitude of defenses present in normal cells 
(Hanahan and Weinberg, 2000). The focus of cancer research has been on identifying 
‘oncogenes’ which have mutations that profess dominant gain of function and ‘tumor 
suppressors’ with mutations causing recessive loss of function that may drive 
tumorigenesis. Pathological analysis of tumors reveal the progression of tumorigenesis 
from normalcy through a succession of intermediate pre malignant states into metastatic 
cancers (Hanahan and Weinberg, 2000). It is becoming increasingly apparent that a large 
contingent of genes each contributing to varying extent may be responsible for promoting 
tumor formation (Luo and Elledge, 2008; McMurray et al., 2008). And while the 
identification of mutations in putative oncogenes and tumor suppressors may have been 
made easy by high throughput methods like microarray technology (Wood et al., 2007), 
deciphering the functional relevance of each will lead to progress in our quest for a cure 
for cancer. 
With the mapping of the genome and the ensuing rapid progress in genomic and 
proteomic technologies, in detail characterization of molecular mechanisms of drug 
action are now possible allowing for designing, screening and evaluating new compounds 
that are more effective and less likely to produce drug resistance (Araujo et al., 2007; 
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Terstappen et al., 2007). These new targeted drugs may be designed to invoke varied 
pathways of signal transduction and medical science could soon move towards 
personalized therapies (Anderson et al., 2006). 
Accordingly, the great and urgent need presently is to investigate the role of each of the 
plenitude of genes and proteins important in the progression of cancer. 
 
2.   NUCLEAR RECEPTORS 
 
The nuclear receptors are a superfamily of structurally conserved transcription factors 
that regulate diverse aspects of development and homeostasis.  
 
2.1   Classification of nuclear receptors 
 
The nuclear receptor superfamily comprises about forty nine human receptors which are 
classified into seven sub-families based on amino acid homology which is also important 
in its nomenclature (1999). They have also been classified based on their ligand binding 
and and DNA-binding properties (Chawla et al., 2001; Mangelsdorf et al., 1995) as (1) 
classical nuclear receptors- these include the extensively characterized glucocorticoid and 
esterogen receptors, (2) the orphan nuclear receptors - whose naturally occurring ligands 
are not known, and (3) the ‘adopted’ orphan nuclear receptors which include receptors 
whose cognate naturally occurring ligands were initially unknown but have subsequently 
been identified like the PPARs and LXR (Chawla et al., 2001; Glass and Ogawa, 2006; 
Mangelsdorf et al., 1995). 
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The first nuclear receptor to be cloned was the glucocorticoid receptor in 1985 and 
subsequently the nuclear receptor superfamily has been extensively studied. The 
availability of purified hormones and antibodies enabled the discovery of the first 
receptors, low stringency hybridization screening and genetic and molecular cloning 
techniques permitted the recognition of other members of the family based on sequence 
homology especially at the DNA binding domain (Mangelsdorf et al., 1995). The 
identification of the ecdysone receptor as a member of the nuclear receptor superfamily 
demonstrated the ubiquitous nature of these receptors (Mangelsdorf et al., 1995). Several 
paralogous genes that originated by gene duplications characteristic of vertebrate lineage 
encode receptors for a given ligand (Laudet et al., 1992) (if a gene in an organism is 
duplicated to occupy two different positions in the same genome, then the two copies are 
paralogous). The two oesterogen receptors ER alpha and ER beta which originate from2 
different genes from 2 different chromosomes show distinct pharmacological profiles and 
expression patterns. These paralogous genes may account for the signal diversity and 
specificity in nuclear receptor family. Paralog selective ligands for ER alpha and ER beta 
have been synthesized. 
 
Many commonly used drugs target nuclear receptors like tamoxifen –which targets 
oesterogen receptors (targeted in breast cancer), thiazolidenediones for peroxisome 
proliferator-activated receptor gamma (targeted in type 2 diabetes) and dexamethasone 
for glucocorticoid receptor (targeted in inflammatory disease) (Gronemeyer et al., 2004). 
RXR agonists like 9-cis-retinoic acid (Panretin) and a synthetic analog (Targetin) are now 
approved by the Food and Drug Administration as compounds for cancer (Evans, 2005) 
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reflecting the growing importance of nuclear receptor biology in the pharmaceutical 
industry. 
 
2.2   Nuclear receptors as modular proteins 
 
Nuclear receptors were initially understood primarily as ligand regulated transcription 
factors that modulate target gene transcription. Even before the first genes encoding 
nuclear receptors were cloned it was known that they are modular proteins with 3 major 
domains (Wrange and Gustafsson, 1978). Nuclear receptors possess a N terminal 
transactivation domain of variable length and sequence called AF1 which is recognized 
by coactivators and transcription factors, a highly conserved DNA binding domain 
composed of two zinc fingers that set nuclear receptors apart from other DNA binding 
proteins, and a largely conserved C terminal domain which has sufficient variation to 
allow for ligand selectivity and possesses a ligand induced activation function called AF2 
which is important in transcriptional coregulator interactions.  
 
2.2.1 Nuclear receptor co-factors 
 
The response of nuclear receptors to particular ligands is determined by the set of 
proteins this nuclear receptor interacts with which include transcriptional cofactors like 
corepressors or coactivators for interaction with other nuclear receptors. In the absence of 
ligand, the LBD of many nuclear receptors is bound to transcriptional corepressors 
(NCoR1, NCoR2, SMRT) which recruit transcriptional complexes that contain specific 
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histone deacetylases (HDACs). These deacetylases generate a condensed chromatin 
structure over the target promoter which results in gene repression (Heinzel et al., 1997; 
Nagy et al., 1997).  Genetic and biochemical data have uncovered a multitude of factors 
especially transcription factors that are involved in nuclear receptor function. Nuclear 
receptors being transcription factors bind to a promoter and modulate transcription by 
recruiting transcriptional coregulators and components of the basal transcriptional 
machinery. In the absence of ligand, or, in the case of ER when bound to partial 
antagonists like tamoxifen (Lavinsky et al., 1998), NRs recruit repressive complexes to 
target promoters, these include HDACs, ATP dependant remodeling complexes and 
corepressors such as  SMRT and NCoR (Metivier et al., 2006). Thus superimposed on the 
nuclear receptors are classes of cytoplasmic and nuclear proteins and chromatin 
remodeling/ transcription complexes along with RNA transcripts that act as chaperones 
or components in signaling cascades. Also many forms of post-translational modification 
like histone acetylation, methylation, protein ubiquitination, sumoylation, and 
phosphorylation have defined crucial roles in coactivator and corepressor activity and 
consequently on nuclear receptor function (Levine and Tjian, 2003). The concept that 
ligands act by removing histone deacetylases from the vicinity of the transcription 
complex and recruit histone acetyltransferases as a molecular mechanism has become a 
important theme in  nuclear receptor action (Evans, 2005). The NURSA – the  nuclear 
receptor signaling atlas has been established with the aim of characterizing nuclear 
receptor function, regulation of nuclear receptors by coregulators, to identify downstream 
targets of nuclear receptors and integrate information on nuclear receptors through 
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NURSA bioinfomatics tools and make it available at a web accessible venue- 
www.nursa.org (Margolis et al., 2005). 
 
2.2.2 Specificity of target genes   
 
The promoters of the target genes of nuclear receptors possess a hormone response 
element (HRE) and the DNA binding domain of nuclear receptors recognize it and bind 
to it. A consensus hexanucleotide  sequence usually present as a pair is a common feature 
of HREs but the sequence and the spacing between the hexanucleotide pair show 
considerable variation and account for the specificity in interaction of the nuclear 
receptor and target gene (Tata, 2002). Steroid hormone receptors have a characteristic 
motif consisting of two hexads in palindromic configuration separated by three 
nucleotides. There is variability in the hexad sequences in this group of receptors. 
However non steroid receptors (Thyroid hormone receptor, RXR, PPARs, Vitamin D 
receptor, RAR) have the same HRE which are organized as direct repeats separated by 
one to five nucleotides. This arrangement of the HRE was termed the 1-2-3-4-5 rule by 
Evans and colleagues in 1990. Non steroidal nuclear receptors that function as 
heterodimers with RXR recognize the direct repeat of the hexad ‘AGGTCA’ which is 
separated by one to 5 nucleotides, and depending on the spacing are specific for PPAR, 
RAR, VDR, TR, NR4A1. Many of the orphan receptors identified have been found to 
heterodimerise with RXR which thus fine tunes and expands the repertoire of signaling 
pathways (Mangelsdorf et al., 1995). Some RXR heterodimers are also activated by RXR 
ligands (rexinoids) and therefore rexinoids may have a large impact on cell homeostasis 
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(Repa et al., 2000). It is now increasingly clear that greater complexity at the genetic 
level in higher organisms is a function of more elaborate regulation of gene expression 
using multiprotein transcription complexes and diverse cofactors and DNA elements like 
enhancer  sequences spread over several 100kB  rather than a greater number of genes 
that encode functional proteins, and nuclear receptors are a case in point showing 
elaborate and sophisticated control of gene expression (Levine and Tjian, 2003). 
 
2.3  Orphan nuclear receptors 
 
The subclass of ‘orphan’ nuclear receptors show the structurally conserved features of the 
nuclear-receptor superfamily, but they have not been linked to naturally occurring ligands 
(Berg, 1989; Mangelsdorf et al., 1995).  
 
2.3.1 Orphan nuclear receptors as lipid sensors 
 
Many orphan receptors have been attributed to be ‘lipid sensors’ and bring about gene 
expression changes as a response to specific lipid levels, especially in contrast to the 
classical nuclear receptors which respond to hormone levels regulated by negative 
feedback control of the hypothalamic- pituitary axis (Chawla et al., 2001). Steroid 
hormones circulate in the body and reach their target tissues where they bind their 
receptors with high affinity (dissociation constant Kd = 0.01 to 10nM). Orphan nuclear 
receptors and adopted orphan nuclear receptors on the other hand respond to dietary 
lipids, and the concentration of these lipids is not under a well governed feedback control. 
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Also these receptors bind their lipid ligands with much lower affinities (>1 to 10 uM), 
and therefore are now believed to be affected by change in dietary levels of lipids, and 
are important in maintaining lipid homeostasis by controlling genes important in lipid 
metabolism, storage, transport and elimination (Chawla et al., 2001). RXRs are activated 
by dietary lipids like docosahexaenoic acid, phytanic acid which is a toxic plant lipid, and 
methoprene acid an insecticide derivative (de Urquiza et al., 2000; Giguere, 1999). The 
PPARs are activated by polyunsaturated fatty acids and eicosanoids (Willson et al., 
2000), Liver X Receptors by naturally occurring oxysterols like 24(S)-hydroxycholesterol 
(Nilsson et al., 2001). Thus the orphan nuclear receptors decipher signals from dietary 
nutrients, environmental toxins and intermediary metabolites generated during 
metabolism while the classical nuclear receptors respond to signals from endocrine 
glands. 
 
2.4 NR4A nuclear receptors 
 
The NR4A family includes NR4A1 (Nur77, NGFI-B, TR3), NR4A2 (TINUR, NOT, 
Nurr1) and NR4A3 (NOR-1, TEC, CHN, MINOR). NR4A family members share greater 
than 97% homology in their DNA binding domains. They also display 37 – 53% 
homology in the N terminal transactivation domains and 53 - 77% in the C terminal 
ligand binding domains (Fu et al., 2007). NR4A receptors have been shown to be 
immediate early genes (Maruyama et al., 1995) and have been found in a widespread 
array of mouse tissues with low or moderate levels of expression (Bookout et al., 2006) 
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and their expression levels have been found to vary in a circadian manner (Yang et al., 
2006).  
 
2.4.1 NR4A hormone response elements 
 
The NR4A family members can bind to the nerve growth factor inducible response 
element (NBRE) ‘AAAGGTCA’ as monomers and activate transcription. The NBRE is 
similar to but functionally distinct from elements recognized by the estrogen and thyroid 
hormone receptors (Mangelsdorf et al., 1995; Wilson et al., 1991). They may also bind as 
dimers the Nur77 response element (NurRE) ‘TGATATTTn6AAATG’, which has been 
identified as a target of CRH-induced Nur77 in the pro-opiomelanocortin (POMC) gene 
promoter (Philips et al., 1997). The NR4A1 and NR4A2 members may also 
heterodimerise with RXR at the DR5 consensus response element 
GGTTCACCGAAAGGTCA’ (Forman et al., 1995; Perlmann and Jansson, 1995; 
Zetterstrom et al., 1996), however, NR4A3 does not (Zetterstrom et al., 1996).  
All three members of the family are induced by forskolin and 12-O-
tetradecanoylphorbol-13-acetate, melanocyte stimulating hormone (MSH) (Smith et al., 
2008), but other agonists like retinoic acids induce them differentially (Maruyama et al., 
1997). NR4A nuclear receptors are key regulatory factors involved in modulation of 
atherosclerotic lesion macrophages and have a protective role in atherosclerosis by 
reducing the uptake of oxidized low-density lipoprotein (ox-LDL) as well as the 
decreasing inflammatory response in human macrophages (Bonta et al., 2006). 
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2.4.2 NR4A mediated regulation of transcription factors 
 
NR4A nuclear receptors have been described to transrepress other transcription factors, 
like the E26 transformation specific sequence (ETS-1) on the matrix metalloproteinase 
promoter in mouse embryonic fibroblasts where transcriptional antagonism has been 
shown between NR4A2 and ETS1, nuclear factor kappa beta (NFkB) which regulates the 
expression of steroidogenic enzyme genes and NR4A1 stimulates the promoter activity of 
these genes in leydig cells, and estrogen related receptor 1 in osteoblasts where NR4A2 
activates the osteopontin promoter and this is repressed by ERRs, and NR4A1 and 
NR4A3 inhibited ERR mediated transactivation. ERRs and NR4A receptors thus repress 
each other but the individual members of these receptor subfamilies differed in their 
abilities to repress (Hong et al., 2004; Lammi et al., 2007; Mix et al., 2007). 
 
2.5   NR4A1 
 
NR4A1 was first cloned in 1988 as one of the early response genes induced in response 
to serum in fibroblasts and nerve growth factor in rat pheochromocytoma cell line and the 
sequence was found to have elements that contribute to its instability three repeats of 
‘ATTTA’ in its 3’ non coding sequence and a sequence rich in proline, glutamic acid,  
serine and threonine (PEST sequence) which is often associated with short lived proteins 
like fos and myc (Hazel et al., 1988; Milbrandt, 1988).  
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NR4A1 has since been found to be induced by stress, adrenocorticotropin (ACTH) or 
cyclic AMP (cAMP), membrane depolarization in PC12 cells by neurotransmitters, 
growth factor treatment (Hazel et al., 1991), and is important in the control of the 
hypothalamic–pitutary-adrenocortical axis, NR4A1 has been shown to be important in 
regulating gene expression in  several tissues important in the hypothalamo- pituitary- 
adrenal axis like the pituitary –where it affects pro opiomelanocortin gene (POMC) 
(Lavoie et al., 2008), the ovary- where it causes transcriptional stimulation of 20a-HSD 
which regulates levels of progesterone (Stocco et al., 2000), and the adrenals  where it is 
important in regulating levels of 3-Hydroxysteroid dehydrogenase type 2 (HSD3B2), a 
steroid-metabolizing enzyme that is essential for adrenal production of 
mineralocorticoids and glucocorticoids (Bassett et al., 2004) and steroidogenesis in leydig 
cells of the testis (Song et al., 2001), however, no irregularities have been  reported in 
basal regulation of hypothalamic and pituitary functions as well as adrenocortical 
steroidogenesis in NR4A1 -/-  mice, as demonstrated by normal levels of ACTH, 
corticosterone, and P450c21 mRNA in the knockout mice - possibly due to functional 
redundancy by other family members (Crawford et al., 1995).  
 
2.5.1   Regulation of NR4A1 
 
Regulation of NR4A1 gene expression has been shown in MA10 leydig tumor cells to be 
dependant on CREB and AP1 family proteins (Inaoka et al., 2008). T cell receptor 
induced apoptosis in thymocytes is mediated by myocyte enhancer factor 2 MEF2 
controlled expression of NR4A1 (Youn et al., 1999). Regulation of NR4A1 in T cell 
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acute lymphoblastic leukemia is by MEF2C which inhibits expression of NR4A1 (Nagel 
et al., 2008). 
 
NR4A1 is found to be important in lipid metabolism by controlling levels of sterol 
regulatory element binding protein 1 (SREBP1c), and SREBP1 directly controls 
transcription of multiple genes involved in triglyceride synthesis it is a major regulator of 
lipid homeostasis in the liver (Pols et al., 2008). 
 
2.5.2 NR4A1 in apoptosis 
 
The role of NR4A1 in apoptosis was recognized when inhibition of NR4A1 expression 
inhibited apoptosis in T cell receptor stimulated cells (Liu et al., 1994; Woronicz et al., 
1994). And more recently in vitamin k induced apoptosis in ovarian cancer cells 
apoptosis was found to be associated with NR4A1 levels and silencing NR4A1 transcript 
prevented apoptosis (Sibayama-Imazu et al., 2008).  NR4A1 has been shown to  
translocate from the nucleus to the mitochondria upon various drug induced apoptotic 
stimuli (Li et al., 2000; Sibayama-Imazu et al., 2008),  interact with Bcl-2 in the 
mitochondria and causes a conformational change in Bcl-2 making it proapoptotic. Bcl-2 
was found to be necessary for the apoptotic effect of NR4A1 and its mitochondrial 
targeting as cells bereft of Bcl-2 either endogeneously or by silencing of Bcl-2 through 
siRNA showed aberrant localization of NR4A1 and had limited apoptotic response (Lin 
et al., 2004). Also, it was found that the transactivation by NR4A1 which was seen with 
growth stimuli like EGF and caused reporter gene transcription was not induced by 
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apoptotic stimuli like TPA, ionophore or etoposide. Thus its transactivation activity has 
been found to be unimportant for the apoptotic function (Li et al., 2000). A recent report 
has also shown that silencing of NR4A1 and NR4A2 in melanocytes impairs their ability 
to repair DNA lesions following UV irradiation (Smith et al., 2008). Another recent 
report suggests that in thymocytes both NR4A1 and NR4A3 translocate to the 
mitochondria and associate with Bcl-2 and impact apoptosis (Thompson and Winoto, 
2008). 
 
NR4A1 is also shown in a microarray study to induce the proapoptoic genes FasL and 
TRAIL in mouse thymocytes (Rajpal et al., 2003).  Also in transgenic mice 
overexpressing full length NR4A1 cDNA in the thymus which induces apoptotic cell 
death in thymocytes, the Fas ligand transcript and protein levels were shown to be 
upregulated but not that of the Fas receptor (Weih et al., 1996). 
 
2.5.3 NR4A1 binding elements 
 
Three NR4A1 binding elements have been identified -  NBRE (NGFI-B response 
element) ‘AAAGGTCA’ that binds monomers of NR4A1 (Wilson et al., 1991), the 
NurRE (Nur77 response element) that binds homodimers of NR4A1 
‘TGATATTTn6AAATG’, which has been identified as a target of corticotrophin 
releasing hormone CRH-induced NR4A1 in the pro-opiomelanocortin (POMC) gene 
promoter (Philips et al., 1997) and the DR-5 binding heterodimers with proteins of the 
RXR family (Forman et al., 1995). However, whereas RXR is inhibited in the RXR-RAR 
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heterodimer, NR4A1 and NR4A2 promote efficient activation in response to RXR 
ligands and therefore shift RXR from a silent to an active heterodimerization partner. The 
apoptotic function of NR4A1 has been found to be independent of its hormone response 
element HRE (NBRE or NurRE) binding but mitochondrial targeting and interaction with 




NR4A2 double knockout mice show embryonic lethality and NR4A2 heterozygous mice 
lack mesencephalic dopaminergic neurons, which are critical for motor function (Jiang et 
al., 2005). NR4A2 heterozygous mice appear normal at birth but develop motor deficits 
resulting from reduced numbers of dopaminergic neurons and lower dopamine levels, 
therefore, NR4A2 is believed to be important in control of both the differentiation and the 
maintenance of these dopaminergic cells. 
Mutations in NR4A2 have been identified to be associated with Parkinson’s disease (Le 
et al., 2003), missense mutations in exon 3 and a point mutation in exon 1 of NR4A2 
have been reported in disorders related to dopaminergic dysfunction such as 
schizophrenia and manic depression (Buervenich et al., 2000). NR4A2 is essential for the 
development and maintenance of midbrain dopaminergic neurons, the cells that 
degenerate during Parkinson’s disease, by promoting the transcription of genes involved 
in dopaminergic neurotransmission. 
Misregulation of this gene may be associated with rheumatoid arthritis. Enhanced 
expression of NR4A2 but not NR4A1 or NR4A3 is observed in synovial tissue of patients 
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with arthritis compared with normal subjects. Proinflammatory mediators PGE2, IL-1, 
and TNF alpha markedly enhance NR4A2 transcription (McEvoy et al., 2002). 
Regulation of NR4A2 has been shown to be mediated by the transcription factors CREB 
and NF-kB which bind to the NR4A2 proximal promoter under basal conditions in 
freshly explanted RA synovial tissue (McEvoy et al., 2002). 
 
ERK2 kinase has been shown to phosphorylate NR4A2 on multiple sites in SH-SY5Y 
cells and this may regulate NR4A2 activity on tyrosine hydroxylase expression which is 
important in Parkinson’s disease (Zhang et al., 2007). NR4A2 may be regulated by wnt 
signaling pathway.  In the absence of beta-catenin, NR4A2 is associated with Lef-1 in 
corepressor complexes. Beta-catenin binds NR4A2 and disrupts these corepressor 
complexes, leading to coactivator recruitment and induction of Wnt and NR4A2 
responsive genes (Kitagawa et al., 2007). 
 
NR4A2 and NR4A1 are both implicated in the response of melanocytes to ultra violet 
irradiation and the subsequent requirement of removal of cyclobutane pyrimidine dimers. 
Silencing NR4A1 and NR4A2 impaired the repair response of the melanocytes (Smith et 
al., 2008). However, in another report, silencing NR4A2 has been implicated with 
increasing anoikis, which is a form of cell death associated with disadherence from 





2.7   NR4A3 
 
NR4A3 in particular came into focus with the observation of a recurrent t(9;22) 
(q22;q12) chromosome translocation that has been described in extraskeletal myxoid 
chondrosarcoma (EMC). A chromosome 22 breakpoint occurred in the EWS gene, and a 
transcript was found as an in-frame fusion of the 5' end of EWS to NR4A3 (Labelle et al., 
1995). More recently, NR4A3 has been implicated in modulation of insulin sensitivity; 
hyperexpression of NR4A3 increased the ability of insulin to augment glucose transport 
activity, suppression of NR4A3 has been shown to reduce the ability of insulin to 
stimulate glucose transport (Fu et al., 2007). NR4A3 levels are found increased in 
senescence in a microarray based study (Hardy et al., 2005). NR4A3 along with NR4A1 
show high induction in beta adrenergic receptor signaling in skeletal muscle cells where 
it is important in energy usage, lipolysis and heat production. Silencing the NR4A1 or 
NR4A3 transcripts attenuates the response of genes involved in lipid use and energy 
balance (AMP-activated protein kinase-gamma3, uncoupling protein (UCP)-3, GLUT4 in 
the case of silencing NR4A1 and FABP4, CAV3, UCP2 in the case of silencing NR4A3) 
(Pearen et al., 2006).  
NR4A3 expression has been found to be inducible with a large number of agonists 
including forskolin, 12-O-tetradecanoylphorbol-13-acetate (tumor promoter TPA) 
(Bandoh et al., 1995), retinoic acids (Maruyama et al., 1997), calcium ionophore 
(Ohkubo et al., 2000), anti CD3 antibody (Cheng et al., 1997), mechanical agitation 
(Bandoh et al., 1997), growth factors (Martinez-Gonzalez et al., 2003; Rius et al., 2006), 
6 mercaptopurine (antineoplastic and anti inflammatory drug) (Wansa et al., 2003), NDP- 
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MSH ([Nle4,D-Phe7]- α-MSH) the Melanocortin-1 Receptor agonist (Smith et al., 2008), 
parathyroid hormone (Pirih et al., 2003), cadmium exposure (Shin et al., 2003), low 
density lipoproteins (Rius et al., 2004), formoterol, isoprenaline a beta-adrenergic 
receptor agonist in skeletal muscle cell line where silencing NR4A3 was shown to result 
in changes in gene expression of genes involved in lipid homeostasis (Pearen et al., 
2006), insulin, and by thiazolidinedione drugs (pioglitazone and troglitazone) (Fu et al., 
2007).  
NR4A3 transactivates gene expression in a activation function 1 (AF1) dependant 
manner and can recruit coactivators, specifically the steroid receptor coactivator 2 (SRC-
2) and p300 which recruit DRIP205 which in turn is part of a complex that regulates 
nucleosome structure and has histone acetyltransferase activity (Wansa et al., 2003).  
 
2.7.1   Regulation of NR4A3 
 
The sequences required in the promoter of NR4A3 for response to the calcium ionophore 
induced cell death was found by a promoter deletion study to be a 53bp sequence 
upstream from the transcription initiation site which contains three copies of the cAMP 
response element (CRE) (Ohkubo et al., 2000). The response of NR4A3 was inhibited by 
the prescence of calcium chelator (BAPTA-AM), PKA inhibitor, PKC inhibitor (GF-
109230X), MAPK (p44/42 and p38) inhibitors (PD98059, SB203580), suggesting that 
NR4A3 transcription may be governed by several pathways (Martinez-Gonzalez et al., 
2003; Rius et al., 2004). Blocking PKA signaling by PKA inhibitor H89 was found to be 
important in lowering NR4A3 induction upon parathyroid hormone treatment, but 
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blocking PKC signaling using overnight pretreatment with PMA to deplete PKC did not 
affect NR4A3 mRNA levels on induction with parathyroid hormone in osteoblast cells 
(Pirih et al., 2003). Thus regulation of NR4A3 may be cell type and stimulus specific. 
 
2.7.2   NR4A3 in apoptosis 
 
The first indication that NR4A3 may have a role in apoptosis came from a study in 1997 
which showed that in thymocytes NR4A3 is induced upon T cell receptor stimulation and 
constitutive expression of NR4A3 leads to massive T cell apoptosis (Cheng et al., 1997). 
Another study analyzing gene expression outcomes of patients receiving chemotherapy 
for diffuse large B-cell lymphoma found that patients with higher expression of NR4A3 
(among other genes) tend to have better prognosis (Shipp et al., 2002). More recently, in 
mice lacking both NR4A3 and NR4A1 it was shown that NR4A1 and NR4A3 together 
behave like tumor suppressors and their abrogation leads to tumorigenesis (Mullican et 
al., 2007). In thymocytes, engagement of the TCR correlates with strong induction of 
NR4A1 and NR4A3 and correlates with apoptotic response. NR4A1 and NR4A3 have 
both been found to translocate to the mitochondria, a process that was found to be 
inhibitable by leptomycin B which is a nuclear export inhibitor. The apoptotic response 
was also found to be highly diminished in the prescence of leptomycin B indicating the 
significance of NR4A1 and NR4A3 translocation from nucleus to mitochondria for the 
apoptotic phenotype (Thompson and Winoto, 2008). NR4A1 and NR4A3 were also 
found in this study to co-immunoprecipitate with Bcl-2 and are ascribed with causing a 
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conformational change in Bcl-2 exposing its BH3 domain which is usually buried within 
the folded Bcl-2 protein (Thompson and Winoto, 2008). 
 
3.   APOPTOSIS 
 
Scientists had observed that some cells were destined to die during tadpole and insect 
metamorphosis and in the late 1970s studies on C. elegans showed that 131 of the 1090  
C. elegans somatic cells die during normal development (Degterev et al., 2003). The first 
studies to show regulated or programmed cell death were described in 1993 in  
C. elegans and provided the first insights into the molecular mechanisms of apoptosis 
(Miura et al., 1993; Yuan and Horvitz, 2004; Yuan et al., 1993). Since then there have 
been more than 70,000 papers towards understanding the apoptotic process in general and 
the core apoptotic machinery in mammalian cells shares the features discerned in 
c.elegans. Apoptotic cell death is characterized by distinct morphological changes, cells 
become rounded and retract, undergo nuclear condensation and fragmentation, membrane 
blebbing, formation of apoptotic bodies (which are small intact fragments that exclude 
vital dyes) and involves the sequential activation of caspases which are cysteine proteases 
and are engulfed by phagocytes (Clarke, 1990; Taylor et al., 2008). Apoptosis has a 
significant role during mammalian development and homeostasis, especially in the 
immune system where unwanted cells need elimination. Apoptosis results in controlled 
disintegration which minimizes damage and disruption to neighbouring cells. 
Dysregulation of apoptosis leads to cancer when there is a failure of the apoptotic 
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machinery or autoimmunity or neurodegenerative disease when there is improper 
activation. 
Analysis of apoptosis in mammalian cells has led to identification of multiple  
mammalian homologs of c. elegans proteins, and while the core regulators of apoptosis in 
C. elegans consist of only 4 genes, EGL-1, CED-3, CED-4, CED-9, each has multiple 
mammalian homologues. For example, EGL-1 is functionally similar to BH3 only 
proapoptotic proteins BID, BIM, NOXA, PUMA, BMF, each having specificities that 
may be distinct or they may be partially redundant, increasing the ability of the organism 
to respond differentially to different apoptotic stimuli (Degterev and Yuan, 2008). Also 
the plethora of caspases found in mammalian systems –activator caspases caspase 2, 4, 8, 
9, 10, 12, executioner caspases caspase 3, 6, 7 and inflammatory caspases caspase 1, 5, 
11 have distinct roles and contribute specifically to distinct signaling pathways, loss of 
one caspase can be compensated for by other caspases and as multiple caspases cleave 
common substrates, execution of apoptosis is not affected by loss of a caspase by 
mutation (Degterev et al., 2003; Degterev and Yuan, 2008).  
 
3.1   Intrinsic and extrinsic pathways of apoptosis 
 
The intrinsic pathway of apoptosis is synonymous with mitochondrial pathway which is 
the de facto pathway initiated by ultra violet rays, serum starvation, and by a large 
repertoire of chemotherapeutic drugs. The intrinsic pathway of apoptosis involves 
mitochondrial damage and release of mitochondrial proteins in mammalian cells, and is 
an important means for executing apoptosis. Cytochrome c which is released form the 
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mitochondria forms a ‘apoptosome’ complex along with APAF1 and caspase 9 which 
leads to the conformational change and activation of caspase 9 making caspase 9 capable 
of cleaving and activating downstream caspases including caspase 3, 6 and 7 which now 
carry out the execution phase of apoptosis (Degterev et al., 2003).  
In addition to the mitochondrial (intrinsic) pathway of apoptosis mammalian cells also 
possess a extrinsic pathway which is induced by Fas ligand (FasL), tumour necrosis 
factor alpha (TNFα) and TNF related apoptosis inducing ligand (TRAIL ) where these 
ligands bind to specific death domain receptors and induce the formation of the death 
inducing signaling complex (DISC) (Micheau and Tschopp, 2003; Peter and Krammer, 
1998). This DISC formation activates the upstream caspase caspase 8 which can then 
cleave downstream caspases like caspase 3. The extrinsic pathway may also recruit the 
mitochondrial pathway by cleaving the BH3-only protein BID and the truncated form of 
bid, t-BID then inserts into mitochondrial outer membrane, activates the proapoptoic 
protein BAX or BAK and triggers release of cytochrome c (Wei et al., 2000; Wei et al., 
2001). 
 
3.2   Caspases 
 
Caspases are cysteine aspartic acid specific proteases which cleave their substrate after 
specific tetrapeptide motifs the fourth being an aspartate residue. All caspases have a 
similar domain structure consisting of a propeptide followed by a large and a small 
subunit. The propeptide may be of variable length and may function as caspase 
recruitment domains (CARD) or death effector domains (DED) and these domains allow 
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for interactions with proteins with similar motifs. Caspases typically function as 
heterotetramers , by dimerisation of two heterodimers, and each heterodimer is formed by 
the proteolytic cleavage of the caspase moiety between its large and small subunit 
(Fischer et al., 2003). 
Caspases are normally present in cells as inactive precursor enzymes. Upon activation, 
caspases cleave their substrates, and about four hundred substrates are known (Luthi and 
Martin, 2007) which include components of the cell cytoskeleton, like components of 
actin microfilaments, actin associated proteins, myosin, gelsolin, filamin, spectrins, 
microtubular proteins including tubulins, microtubule associated proteins, and 
intermediate filament proteins including vimentin keratin and nuclear lamins (Luthi and 
Martin, 2007; Taylor et al., 2008). Caspase mediated clevage of the protein kinase  
ROCK1 ( a Rho effector protein, which contributes to phosphorylation of myosin light-
chains, myosin ATPase activity and coupling of actin–myosin filaments to the plasma 
membrane), is regarded to be essential for membrane blebbing (Coleman et al., 2001; 
Sebbagh et al., 2001). Activation of ROCK1 is also important in nuclear fragmentation as 
the nuclear lamina is surrounded by a mesh of actin and reorganization of the actin-
myosin system disrupts the nuclear envelope (Croft et al., 2005). Caspases also target 
proteins important in housekeeping functions of the cell, proteins important in 
transcription, translation, fragmentation of Golgi apparatus, ER (Taylor et al., 2008). 
 
3.2.1   Caspase independent cell death  
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Caspases are not absolutely essential for cell death under proapoptotic conditions, as 
reflected by the inability of caspase inhibitors to protect cells from cell death (Amarante-
Mendes et al., 1998; McCarthy et al., 1997; Xiang et al., 1996). The cells dying under 
these conditions did not show characteristics of apoptosis like activation of caspases 
nuclear condensation or DNA fragmentation and instead were highly vacuolated and 
showed loss of plasma membrane integrity and thus the cells showed cell death, only 
with different morphological characteristics. This CICD may occur as a result of 
mitochondrial outer membrane permeabilisation (MOMP) where the integrity of the 
mitochondria is compromised (Green and Kroemer, 2004). Mitochondria release 
proapoptotic molecules that activate caspases (e.g. cytochrome c) or induce cell death 
with factors that are not dependant on caspases.  The morphology of a cell undergoing 
CICD undergoes minimal alterations until late stages of the process which is distinctly 
different from apoptosis (Chipuk and Green, 2005). 
 
3.3   Mitochondrial outer membrane permeabilization 
 
Mitochondrial outer membrane permeabilization (MOMP) leads to the release of many 
proteins normally found in the intermembranal space between the mitochondrial inner 
and outer membranes  like cytochrome c, apoptosis inducing factor AIF, endonuclease G, 
Omi/HtrA2. This is accompanied by a dissipation of the mitochondrial transmembrane 
potential. MOMP can occur without the loss of electron transport, ATP production, or 
mitochondrial protein import, however, these functions eventually diminish and may 
result in CICD. 
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Many proteins are known to modulate MOMP, and two distinct mechanisms are 
attributed with regulation of the MOMP.  
In the first model, a ’pore’ is formed by the ANT in the inner mitochondrial membrane 
and the VDAC in the outer mitochondrial membrane and cyclophilin D in the matrix 
(Green and Kroemer, 2004; Zamzami and Kroemer, 2001). And a sudden increase in 
permeability of the inner mitochondrial membrane to low molecular mass solutes occurs 
resulting in mitochondrial membrane permeabilisation.  Reconstitution of a complex 
containing VDAC, ANT and cyclophilin D yields a MPT like pore in proteoliposomes 
(Crompton et al., 1998). The components of the pore may include a ‘complex’ named the 
permeability transition pore complex (PTPC) which include, along with VDAC, ANT 
and cyclophilinD,  the peripheral benzodiazepine receptor (in the outer mitochondrial 
membrane), creatine kinase (in intermembranal space), hexokinase (tethered to VDAC in 
the outer mitochondrial membrane) (Zamzami and Kroemer, 2001). Many compounds 
that affect the PTPC components can modulate MPTP opening and consequently 
apoptosis, like cyclosporine A which acts on cyclophilin D , and bongkrekate which is an 
ANT ligand (Zamzami and Kroemer, 2001). The inner mitochondrial membrane allows 
water and molecules up to 1.5 kDa in size to pass through. And on the outer 
mitochondrial membrane VDAC is permeable to solutes of upto 5 kDa, thus allowing for 
free exchange of substrates like NADH, FADH, ATP and ADP between mitochondrial 
intermembranal space and cytosol. However, the inner mitochondrial membrane is 
impermeable to these substrates, and this is fundamental for the generation of the 
electrochemical proton gradient required for oxidative phosphorylation. The 
physiological gating potential at which pore opening occurs is 200 mV, negative on the 
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inside. Pore agonists shift gating potential to more negative values, favouring pore 
opening and pore antagonists cause pore closure. The opening of the permeability 
transition pore leads to transmembrane potential loss as ions equilibriate across the 
membrane, and the matrix swells as water enters. Matrix swelling may cause MOMP 
(Green and Kroemer, 2004).  
The second mechanism for regulation of MOMP is mediated by Bcl-2 family of proteins 
acting on the outer mitochondrial membrane. Anti-apoptotic Bcl-2 family members 
function to block MOMP, while pro-apoptotic members facilitate it. Vesicles composed 
of mitochondrial lipids (without mitochondrial proteins) can be permeabilised by 
recombinant monomeric Bax in the prescence of cleaved Bid (Basanez et al., 2002). Bcl-
2 family members have been shown to interact with PTPC components, as VDAC1 and 2 
isoforms interact with Bax and Bak respectively, VDAC1 having proapoptotic role and 
VDAC2 functions as an antiapoptotic factor by sequestering active Bak (Cheng et al., 
2003), and cells deficient in both Bax and Bak are highly resistant to apoptosis (Letai et 
al., 2002; Shimizu et al., 1999; Wei et al., 2001), and Bcl-2 and Bcl-XL may inhibit MPT 
by interacting with and closing the VDAC channel (Shimizu et al., 2000; Shimizu et al., 
1999; Zheng et al., 2004). Recently it has been shown that VDACs are dispensable for 
induction of mitochondrial permeability transition MPT and cell death as mitochodria 
lacking VDAC undergo MPT in vitro, and fibroblasts lacking VDAC isoforms show the 
same mitochondrial response as control cells (Baines et al., 2007; Galluzzi and Kroemer, 
2007). ANT isoforms have also been shown to be not prerequisite for MPT (Kokoszka et 
al., 2004). It is now proposed that cyclophilin D may act as a ‘PTPC organizing centre’ 
directing the formation of a complex where VDAC and ANT isoforms may be at least 
 26
partially redundant and become included in the PTPC depending upon their availability 
or on the nature of the apoptoic stimulus (Galluzzi and Kroemer, 2007). 
 
3.4   Apoptogenic and inhibitory proteins involved in apoptosis 
 
Cytochrome c  
Cytochrome c is an essential component of the respiratory chain, and upon release into 
the cytosol it forms with Apaf-1 and caspase 9 the ‘apoptosome’ in the prescence of ATP, 
which activates caspase 9 and consequently the downstream caspases.   
 
IAPs 
The inhibitors of apoptotic proteins (IAPs) present in the cytosol bind to and inhibit 
caspases and prevent their inappropriate activation. The IAPs possess the baculoviral IAP 
repeat (BIR) motifs which enable them to bind caspases (Vaux and Silke, 2005). 
 
Smac/DIABLO and Omi/HtrA2 
Smac/DIABLO (second mitochondria-derived activator of caspase) and Omi/HtrA2 are  
mitochondrial proteins which are released upon apoptotic stimulus from the mitochondria 
into the cytosol where they binds to and neutralizes the IAP proteins, which results in 
ubiquitin mediated proteosomal degradation of the IAPs allowing for apoptosis to 






Protease endonuclease G is also released from the mitochondrial intermembranal space 
into the cytosol and subsequently translocates to the nucleus. Endonuclease G  is an 
evolutionarily conserved protein and is thought to participate in mitochondrial biogenesis 
by regulation of mitochondrial synthesis and repair. Endonuclease G can induce caspase 
independent DNA fragmentation in isolated nuclei and can cleave chromatin DNA into 
nucleosomal fragments (Li et al., 2001). 
 
AIF 
AIF the apoptosis inducing factor is, like cytochrome c, a mitochondrial flavoprotein and 
resides in the mitochondrial intermembranal space where it has a oxidoreductase 
function. On apoptotic trigger it translocates to the nucleus where it possibly along with 
endonuclease G causes chromatin condensation as well as high molecular weight DNA 
cleavage (Broker et al., 2005). HSP70 inhibits the translocation of AIF to the nucleus 
through its interaction with the N terminal domain of AIF and inhibits its apoptogenic 
effects (Ravagnan et al., 2001). AIF lacks intrinsic nuclease activity and requires a 
binding partner to induce DNA cleavage and and AIF can cause overactivation of poly 
(ADP-ribose) polymerase-1 (PARP1). AIF release is independent of caspase activation as 







Poly(ADP-ribose) polymerase-1 (PARP1) is a nuclear enzyme that plays an essential role 
in responding to DNA damage by facilitating DNA repair. It is rapidly activated by DNA 
strand breaks. Once activated, PARP1 transfers 50-200 molecules of ADP ribose to 
several nuclear proteins including histones and PARP1 itself. Overactivation of PARP1 
can lead to cell death, including caspase independent cell death (Degterev and Yuan, 
2008). PARP1 mediated cell death is proposed  to be partly because of energy reduction 
resulting from using up of NAD+ reserves. The NAD+  pool of a cell is largely contained 
in the mitochondria and therefore depletion in NAD+ because of PARP-1 activity may 
result in alterations in the mitochondria (Virag et al., 1998; Yu et al., 2002). PARP1 
activation also leads to release of the inflammatory cytokine high mobility group-B1 
(HMGB1), which alerts immune cells to the prescence of dangerous cells having 
damaged DNA (Ditsworth et al., 2007). During apoptosis, PARP1 is cleaved from it 116 
kDa intact form into 85 kDa and 25 kDa fragments. This process separates the amino-
terminal DNA-binding domain of the enzyme from the carboxy-terminal catalytic domain 
resulting in the loss of normal PARP1 function. Although the role of PARP in apoptosis 
remains to be elucidated, PARP cleavage is considered to be a marker of apoptosis 










Figure 1. Caspase dependant and Caspase-independent routes to cell death: Cell death 
triggers may act at the cell surface receptor which may involve the mitochondria or 
initiate a mitochondrial response directly and  invoke caspase dependant apoptotic 
response and may also elicit various factors that cause cell death in a caspase independent 
















Figure 2. Structure and components of the Permeability Transition Pore Complex: The 
structure of the permeability transition pore complex is believed to constitute of VDAC 
in the outer membrane, adenine nucleotide transferase ANT in the inner mitochondrial 
membrane and cyclophilin D which may act as the PTPC organizing centre and recruits 
the other components. Other PTPC components include creatine kinase (CK), hexokinase 
(HK), peripheral benzodiazepine receptor (PBR). Both pro and antiapoptotic members of 
Bcl-2 family modulate activity of the PTPC by interaction with ANT or VDAC. Many 
inhibitors and facilitators of the mitochondrial membrane permeabilization and their 







3.5   Non apoptotic mechanisms of cell death 
 
When the apoptotic machinery of a cell is disabled, such as by caspase deficiency, non 




Autophagic cell death is characterized by accumulation of double membrane enclosed 
vesicles containing parts of the cytoplasm and intracellular organelles called 
autophagosomes which eventually fuse with lysosomes and the contents are degraded and 
the macromolecules recycled. It is an evolutionarily conserved mechanism central to the 
process of degradation and removal of damaged or misfolded proteins or even whole 
organelles which may be detrimental to the cell or to eliminate long lived protein or 
organelle components. It is of particular significance in nutrient deprivation conditions 
where it recirculates the essential proteins which are essential for meeting the 
bioenergetic needs and metabolic substrates required for cell survival (Maiuri et al., 
2007). So autophagy may result in adaptation of the cell to promote cell survival or, 
depending on the circumstances, autophagy may become the expedient method of cell 
death in apoptosis deficient cells in response to genotoxic or ER stress stimuli (Shintani 
and Klionsky, 2004). For example in apoptosis deficient Bax-/- and Bak-/-  mouse 
embryonic fibroblasts cells massive autophagic cell death is seen which is inhibited by 
knockdown of Atg5 and Beclin1 (which is the mammalian homologue of yeast Atg6) 
(Shimizu et al., 2004). Apoptosis and autophagy may develop simultaneously as a 
 32
response to common stimuli, however their relative contribution to cell death or its 
inhibition may depend on the relative threshold of the cell to the stimulus. Autophagy is 
regulated by a large number of Atg (autophagy related) genes that are conserved from 
yeast to humans. Also proapoptotic BH3 only members of the Bcl-2 family BNIP3 and 
BIK can induce activation of autophagic cell death (Rashmi et al., 2008; Tracy et al., 
2007). 
 
Mitotic catastrophe  
 
This form of cell death is initiated by a failure of the occurance of mitosis caused by a 
defect in cell cycle checkpoints, and results in aneuploid cells which are destined to die 
(Castedo et al., 2004). Failure of the cells to arrest the cell cycle before or at mitosis 
promotes  aberrant chromosome segregation, which results in mitotic catastrophe. Mitotic 
catastrophe is controlled by numerous genes especially transcription factors important in  
cell-cycle , such as the cyclin B1-dependent kinase Cdk1, polo-like kinases and Aurora 
kinases, cell-cycle checkpoint proteins, survivin, p53, caspases and members of the Bcl-2 




Necroptosis came to attention when apoptosis was inhibited by caspase inhibitors and the 
cells were seen to proceed into a morphologically distinguishable non-apoptotic form of 
cell death (Khwaja and Tatton, 1999; Matsumura et al., 2000). Although necroptosis is 
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activated by the same stimuli that result in apoptosis, the morphological features of 
features especially DNA degradation and formation of apoptotic bodies are conspicuous 
by their absence and instead there is organelle swelling, rapid mitochondrial dysfunction, 
plasma membrane permeabilization - which are characteristic of necrosis. Also 
‘necrostatins’ which are small molecules that specifically inhibit necroptosis but not 
apoptosis further delineate the distinct process of necroptosis (Degterev et al., 2005). The 
initiation of necroptosis occurs by the recruitment and activation of a intracellular 
signaling complex which includes the adaptor molecule Rip1 (Holler et al., 2000). The 
kinase activity of Rip1 is essential for necroptosis, and in TNFa induced necroptosis it 
inhibited inner mitochondrial membrane protein Adenine nucleotide translocase (ANT) 
mediated transport of ADP into mitochondria and it is also found to disrupt the 
interaction between ANT and the mitochondrial matrix protein cyclophilin D (Temkin et 




Necrosis is synonymous with uncontrolled cell death and is accompanied by rapid loss of 
membrane integrity and release of cellular contents into extracellular space. The response 
of the immune system is particularly different in its reaction to apoptotic and necrotic 
cells. Necrotic cells release proteins that can be recognized by the immune system like 
the high mobility group protein B1 (HMGB1), uric acid, heat shock proteins, single 
stranded RNA, genomic DNA (Oppenheim and Yang, 2005; Rovere-Querini et al., 2004; 
Shi et al., 2003). However apoptotic cells show plasma membrane alterations that 
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facilitate their removal before the release of their cytoplasmic contents so they do not 
initiate an immune response and are instead engulfed by phagocytes (Taylor et al., 2008). 
 
4.  MICROARRAY TECHNOLOGIES IN INTERPRETING DRUG INDUCED 
SIGNALLING  
 
There has been a great deal of work to try and understand how classical drugs effect 
cancer cells and cause them to undergo apoptosis or other related mechanism like 
senescence or autophagy or necrapoptosis. The central idea is of course that once we can 
decipher the molecular mechanism of drug action we will be able to make more suitable 
judgements  regarding  suitability of the drug for a particular patient whose genetic 
profile is appropriately deciphered. Conventional drugs and the pathways they influence 
have been the subject of immense interest to biologists, and there has been some headway 
in understanding the signal transduction pathways these drugs initiate that ultimately 
results in apoptosis or related mechanism of cell death. The receptors that come into play 
and the mediators of the signal transduction pathway are now being unveiled and these 
new revealations about drug induced signal transduction show ways to counter resistance 
to the drug. Much research has gone into understanding how drugs effect apoptosis 
through p53-dependent stimulation of the Fas/FasL system (Muller et al., 1997; 
Srivastava et al., 1999). This in turn reflects why these drugs may not be successful in 
cases where p53 is non functional, guiding the use of these drugs in a functional p53 
patient cohort. Many studies have focused on finding targets to improve drug sensitivity, 
which can be restored using another drug in combination that, say, allows for inhibition 
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of Akt levels (Wang et al., 2008) (which are important for proliferation) thus allowing for 
designing alternate strategies to combat cancer. 
 
High throughput technologies like microarray analysis are particularly suited to a global 
search for strategies to understand the pathways a drug may invoke, the knowledge of 
which may be used to improve drug potency. Also, microarray technology can benefit 
cancer therapy by allowing the unraveling of the molecular events following drug 
treatment that may be of consequence in therapy. Microarray data is increasingly being 
used to validate new drugs and understand the gene expression profile changes triggered 
by new drugs in development in pre clinical studies (Podar et al., 2006; Takeda et al., 
2007). Gene expression and gene ontology analysis have shown the upregulation of many 
proapoptoic gene ontology groups and a downregulation of genes controlling mitosis, and 
thus microarray experiments server to further delineate drug targeted molecular 
pathways. 
 
However in spite of the enormous advances in technology, especially in genomics and 
proteomics, and with an annual spending of US$50 million by the pharmaceutical 
industry on research and development, there have been only a handful of new and 
successful drugs in the recent years. The approval rate for new drugs which are against 
new targets (proteins that are not known to be targeted by known drugs) are even lower 
(Araujo et al., 2007). And it is to address this dismal picture that there is now a pressing 
need to probe the impact of every mutation in each of the gene products important in the 
progress of tumorigenesis. 
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Also there is a recognition now with new microarray and other data that each tumor is 
unique with its distinct set of molecular derangements and may therefore require an 
individualized therapeutic strategy (Wulfkuhle et al., 2004). 
 
5.   NOVEL PHOTOCHEMOTHERAPEUTIC AGENT C1 
 
5.1   Photodynamic therapy and preactivation 
 
Many compounds have been known to be capable of being excited upon exposure to light 
in the prescence of molecular oxygen when presumably upon absorption of a photon an 
electron in the molecule shifts to a long lived higher energy ‘triplet’ state, and the 
molecule could then collide with particular biomolecules, such as molecular oxygen, with 
the subsequent transfer of energy generating activated oxygen molecules like singlet 
oxygen. It is believed that the light dependant breakdown of chromophores to generate 
novel active compounds and the generation of reactive oxygen species contribute to the 
physiological impact of the activated compound. Several compounds have been tested 
with varying degrees of success with photodynamic therapy for the derivation of 
molecules of interest in cancer therapy including photofrin, purpurins, xanthenes, 
phthalocyanines, oxazines, cyanines, chlorines (Pervaiz, 2001; Pervaiz and Olivo, 2006). 
Photodynamic therapy is an approved treatment mode against some forms of solid 
cancers, precancerous lesions and age-related macular degeneration (AMD) (Pervaiz and 
Olivo, 2006). 
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The process of photoactivation involves exposure of the compound along with its target 
tissue to a specific source of light for a specified period of time which results in the 
formation of new cytotoxic compounds (Pervaiz et al., 1992). Since simultaneous 
exposure of the target to the photosensttizer compound and light are essential in the 
process of photodynamic therapy, its applicability is limited to solid and accessible 
tumors. However in 1990, it was found that this process could be modified and the 
compound could be exposed to light and subsequently used as any anticancer drug. Such 
photoactivation was found to be effective and the phrase ‘preactivated’ was coined to 
reflect that the compound is exposed to light prior to its use in biological systems 
(Pervaiz, 2001).  
 
5.2   The genesis of C1 
 
Preactivated merocyanine 540 (pMC540) has been shown to be specific to leukemia and 
lymphoma cell lines like Daudi (Burkitt’s lymphoma), HL60 (leukemia), histiocytic 
lymphoma (U-937) tumor cells and its cytotoxicity towards normal human cells 
(mononuclear cells) is very low (survival of 85% for normal cells and 20% for tumor 
cells)(Gulliya and Pervaiz, 1989) (Gulliya et al., 1990). In HL60 leukemia and M14 
melanoma cells pMC540 has been shown to mediate its apoptotic effect with cell 
shrinkage, fragmentation of DNA, externalization of phosphatidylserine, activation of 
caspase 3, and PARP1 clevage which are hallmarks of a classical apoptotic response 
(Pervaiz et al., 1998).  
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Previous work on pMC540 treatment of MCF-7  breast adenocarcinoma cells in vitro and 
on MCF-7 cells grown as solid tumors with estrogen stimulation and implanted in 
athymic mice has shown the in vivo effectiveness of pMC540 in suppression of breast 
tumors (Gulliya et al., 1994).  
 
Since pMC540 is a mixture of photoproducts, our lab separated and purified the 
components to investigate the biological activity of the purified photoproducts and we 
narrowed down two of the fractions C1 and C2 which showed efficient induction of 
apoptosis in HL60 and M14 cell lines with largely similar caspase activation, however 
the two compounds differed in their ability to cause mitochondrial swelling and loss of 
transmembrane potential, while C1 caused a loss of transmembrane potential and 
swelling of isolated mitochondria, C2 does not. Both are however effective at inducing 
cytochrome c release from mitochondria (Pervaiz et al., 1999). 
 
The drug C1 has previously been reported by us to cause classical apoptosis with 
activation of caspases, translocation of cytc from the mitochondria to the cytosol, and a 
drop in the transmembrane potential in leukemia cell line HL60 and melanoma cell line 
M14 (Pervaiz et al., 1999).  
 
The drug C1 is a small molecular weight lipophilic compound with the scientific name N, 
N’-Dibutyl-thio-4,5-imidazolindion (MW 242). Its structure comprises of an imidazole 
ring with two butyl side chains. It was originally generated by photoactivation of the 
lipophilic polymethine chromophore merocyanine 540 which generates a mixture of 
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photoproducts (Gulliya et al., 1994), many of which upon isolation and purification have 























PART II   AIMS OF THE STUDY 
 
 
The present study was designed to understand the mechanism of drug induced cell death, 
especially the signals in the initial portion of the signal transduction cascade which 
ultimately leads to cell death. We have in our lab previously purified and characterized a 
novel therapeutic compound ‘C1’ which causes apoptosis in many cell types and is 
especially interesting as it has been observed to generate reactive oxygen species. We 
have in this study used the high throughput microarray technique to comprehend the 




• To establish the key apoptotic features in C1 mediated apoptotic response 
• To seek new or prominent genes that are important players in the signal 
transduction cascade triggered by drug C1 
• To analyse the role of the above factors in the apoptotic response of the cells to 
drug C1 








PART III    MATERIALS AND METHODS 
 
1.   Cell culture 
The human promyelocytic leukemia cell line HL60 and the MCF-7 human breast cancer 
cell lines were obtained from ATCC (Rockville, MD) and maintained in culture in RPMI 
1640 supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, Utah, USA), 
200uM of L-glutamine, 100 IU/ml of penicillin streptomycin solution (Hyclone, Logan, 
Utah, USA) in an incubator with 5% CO2.  
 
2.   Drugs used   
C1 drug (N, N’-Dibutyl-thio-4,5-imidazolindion, MW 242) was prepared as described 
elsewhere (Pervaiz et al., 1999), Staurosporine, Daunorubicin  were purchased from 
Sigma, St. Louis, MO. Cells were plated at a concentration of 1.5 X 105 million cells per 
ml and left for 12-16 hrs before being treated with the drugs at given concentrations. 
 
3.   Viability assay  
To determine the viability of cells to C1, staurosporine or daunorubicin, MCF-7 and 
HL60 cells were treated with increasing concentrations of the compounds  for 18 
hours,24hrs 48hrs or 72hrs as required. Cells were plated at 1 X 105 cells/ml in a 96-well 
plate and viability was determined by the MTT assay. Ten microliters of 5 mg/mL 3-[4,5- 
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was added to each well 
and incubated for 2-3 hours at 37°C. Elution of the precipitate was performed with 100 
μL of DMSO and 10 μL of Tris-Glycine buffer. Cell viability was calculated from the 
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absorption values obtained at 570 nm using an automated enzyme-linked immunosorbent 
assay (ELISA) reader. 
 
4.   Cell proliferation assay  
The extent of cell proliferation was determined using the Cell Proliferation ELISA BrdU 
colorimetric assay kit from Roche. Each well was seeded with 10,000 cells in 100ul 
volume in 96 well TC nunc plates and incubated at 37°C for 24 hrs. Cells were 
transfected using DF1 transfection reagent as described below and after 24 hrs were 
treated with various concentrations of drug C1 for 18 hrs. Incorporation of BrdU was 
assessed according to the manufacturer’s instructions provided with the kit. 
 
5.   Colony formation assay   
MCF-7 cells were plated onto 6 well plates at a concentration of 1.5 X 105 cells per ml 
and after an overnight incubation were treated for 18 hrs with various doses of drug C1 in 
6 well plates. Cells were then washed and 2X104 cells from each well were re-plated into 
100mm culture dishes and left to form colonies over a period of 8–12 days. Culture 
dishes were stained with crystal violet to determine the number of colonies. The number 
of  colonies present in a 1cm X 1cm grid divided into nine sections were counted for each 
plate in triplicates and the average number was used to calculate the number of colonoies 





6.   Cell cycle analysis 
Cells were fixed with 70% ethanol and stained with propidium iodide (PI), using a 38mM 
sodium citrate buffer made in 1X PBS containing PI to a concentration of 10ug/ml and 
250ug/ml of RNaseA PI and RNaseA are both from Sigma, St. Louis, MO, for DNA 
content analysis as described elsewhere (Hirpara et al., 2001). A total of 10,000 events 
were analyzed by flow cytometry (Beckman Coulter, USA) using an excitation 
wavelength set at 488 nm and emission at 610 nm. The data was analysed using the 
WinMDI 2.9 software. 
 
7.   Cell morphology  
The morphology of the cells was analyzed using the Olympus digital camera 
(C4040ZOOM, 4.1 mega pixels) attached to the light microscope (Olympus CK2) at 200 
X magnification. 
 
8.   Caspase activity measurement 
 Caspases 2, 6, 7, 8, and 9 activities were assayed using 7-amino trifluoromethylcoumarin 
and 7-amino-4-methycoumarin-conjugated substrates,  
Ac-VDVAD-AFC that is Ac-Val-Asp-Val-Ala-Asp-AFC (AFC=7-Amino-4-
trifluoromethylcoumarin) for caspase 2, Ac-VDVAD-AFC which is Ac-Val-Glu-Ile-Asp-
AFC  for caspase 6, Ac-DEVD-AFC which is Ac-Asp-Glu-Val-Asp-AFC (AFC = 7-
Amino-4-trifluoromethylcoumarin) for caspase 7, Ac-IETD-AFC which is Ac-Ile-Glu-
Thr-Asp-AFC  for caspase 8, Ac-LEHD-AFC which is Ac-Leu-Glu-His-Asp-AFC  for 
caspase 9 (all from Alexis biochemicals San Diego, CA ). MCF-7 cells (1X105/ml) were 
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treated with various doses of C1 for 4, 6, 8, 12, and 18 hrs. Cells were then harvested and 
washed with 1XPBS, resuspended in chilled cell lysis buffer (BD Pharmingen, San 
Diego, CA, USA), and incubated on ice for 10 min before the addition of 40uM of the 
respective substrates for caspase activity analysis as reported previously (Hirpara et al., 
2001). The fluorescence values were calculated relative to the fluorescence values of 
untreated cells at time 1hr and normalized to protein concentration of the samples and 
plotted as fold increase in caspase activities relative to the untreated sample. 
 
9.   Measurement of transmembrane  potential  
Potential sensitive probe 3, 3’-dihexyloxacarbocyanine iodide (DiOC6, from Molecular 
Probes Eugene, OR, USA) was used to measure change in transmembrane potential. 
Briefly, 1X106 cells were washed once with PBS, then incubated with DiOC6 (40 nM) 
for 15min at 37C, washed again and resuspended in culture medium and immediately 
analyzed by flow cytometry (Coulter EPICS Elite ESP) with excitation set at 488 nm. At 
least 10,000 events were analyzed using WinMDI software. 
 
10.   Western blot analysis  
MCF-7 cells were plated (1.5X105 cells per ml) in 6 well plates or petri plates 100mm 
diameter and treated with C1 at various concentrations for the indicated durations. Cells 
were harvested and washed once with PBS, then lysed with cell lysis buffer (150mM 
NaCl, Tris–HCL 7.4, and 1% Nonidet P40). Protein concentration was determined for the 
lysates with Coumassie Blue reagent (Pierce, IL, USA). Cell lysate (100mg) was then 
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electrophoresed on either 8%, 12%, or 15% polyacrylamide gel before immunoblotting 
for specific proteins.  
For isolation of mitochondrial and cytosolic fractions, cells were incubated for 30 min in 
extraction buffer A (50mM PIPES-KOH (pH 7.4), 200mM mannitol, 68mM sucrose, 
50mM KCl, 5mM EGTA, 2mM MgCl2, and 1mM DTT), supplemented with a cocktail 
of protease inhibitors (1mM PMSF, 10 mg/ml aprotinin, 20 mg/ml pepstatin A, and 10 
mg/ml leupeptin), before homogenization in a dounce homogenizer. The homogenate was 
spun at 400g for 15 min, and the pellet was discarded. The supernatant was spun at 
10,000g for 10 min the pellet was the fraction enriched for mitochondria, was dissolved 
in lysis buffer and stored in -20C till it was used further, and the supernatant the cytosol 
was also stored at -20C till it was used further. Protein blots were probed with anti beta-
actin (Sigma-Aldrich, St Louis, MO, USA) and GAPDH (Santa Cruz Biotechnology, CA, 
USA) as controls for protein loading.  
 
10.1   Antibody list for western blotting 
Cytochrome C (BD Pharmingen, San Diego, CA, USA), Bax (N-20): sc-493 (Santa Cruz 
Biotechnology, Inc., CA, USA), AIF (D-20): sc-9416 (Santa Cruz Biotechnology, 
Inc.,CA, USA), CuZn Superoxide Dismutase (CuZnSOD) (BD Pharmingen San Diego, 
CA, USA), PARP [Poly (ADP-ribose) Polymerase] Monoclonal Antibody (BD 
Pharmingen San Diego, CA, USA), Anti-porin (Hu mitochondrial) VDAC1 antibody 
(Invitrogen, Carlsbad, CA, USA), c-Jun (Cell Signaling Technology, Inc. Danvers, MA, 




p-Jun  (phospho-c-Jun) ser73 (Cell Signaling Technology, Inc. Danvers, MA, USA) 
antibody detects endogenous levels of c-Jun only when activated by phosphorylation at 
Ser73. This antibody also recognizes JunD phosphorylated at Ser100. The transcriptional 
activity of c-Jun is regulated by phosphorylation at Ser63 and Ser73.  
 
10.2   Buffers used  
 
RIPA Lysis Buffer 
50mM Tris HCL pH7.5, 150mM NaCl, 1%Nonidet P40, 1%deoxycholic acid, 0.1% SDS, 
1mM EDTA. Before use, protease inhibitors (1mM PMSF, 10µg/ml Aprotinine, 20µg/ml 
Pepstatin A, 10µg/ml Leupeptine, 1mM NaF, 1mM Na3VO4) were added. 
 
2X Reaction buffer for caspase substrates 






































11. Transfections  
MCF-7 cells were plated in 6, 12 or 96 well plates at a concentration of 1 X 105cells/ml 
in medium without antibiotics. After growth for 24hrs cells were transfected with siRNA 
to NR4A3 (Smartpool, Dharmacon) or NR4A1 (Smartpool, Dharmacon) or both or 
nontargeting siRNA (ON-TARGETplus Non-targeting siRNA #2, Dharmacon) at final 
concentration of 50nM of each siRNA and were transfected using DF1 reagent 
(Dharmacon Lafayette CO) according to manufacturer’s protocol. 24 hrs or 48 after 
transfection cells were treated with complete medium containing indicated drugs at 
specified concentrations for specified time periods.   
 
12. RNA isolation and reverse transcription  
Total RNA was isolated from cells by TRIZOL reagent (Invitrogen, Carlsbad, CA, USA ) 
as described by manufacturer’s instructions with a DNAse (Invitrogen, Carlsbad, CA, 
USA ) treatment step incorporated into the protocol. Each RT reaction contains 2.5 ug of 
total RNA, 1XRT buffer, 10 mM dNTP mix, 2 mM random hexamers, 0.1M DTT, 0.35 
U/ml RNase inhibitor, 100U SuperScriptII  reverse transcriptase (all from Invitrogen,  
Carlsbad, CA, USA) and made up to 20ul with sterile water. RT reaction was carried out 
at 25C for 10 min followed by 42C for 50min and 70C for 15min, and stored at -20C. 
 
13. Real Time PCR  
Two microliters of the 20 ul cDNA reaction volume was used in real-time quantitative 
PCR using ABI PRISM7500 (Applied Biosystems). Normalization was to glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) for human RNA. Fluorescence was measured with 
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the Sequence Detection Systems 2.0 software. PCR was performed in multiplex (both 
target and endogenous control co-amplified in the same reaction) with distinct fluorescent 
dyes. The primers (350 nM) and probe (100 nM) for NR4A3, NR4A1, jun, VDAC1 were 
purchased as kits from Applied Biosystems Assay ID: Hs00175077_m1, 
Hs00374230_m1, Hs99999141_s1, Hs01019082_mH. Human GAPDH endogenous 
control was purchased from Applied Biosystems Foster City, CA. 
 
14. Microarray experiments and data analysis 
cDNA microarrays of approximately 18K array targets were produced using established 
procedureswith cDNA clones from commercial vendors (Incyte and Research Genetics) 
(DeRisi et al., 1996). Identities of array targets were confirmed by resequencing the 
parent clones (Tay et al., 2003). Microarrays were printed with fine-pointed pins onto 
poly lysine treated glass slides. The array of fine pins were controlled by a robotic arm 
that dipped the pins into wells containing the cDNA probes and then depositing each 
probe at designated locations on the glass slide. The resulting grid was then hybridised to 
complementary cDNA targets derived from experimental samples or the common 
reference.  
After depositing DNA on every slide the tips are washed and dried and the process is 
repeated for the next set of DNA samples with the new spots offset a small distance 
relative to previous spots to produce a high-density grid. 
 
Expression profiles were generated from HL60 human promyelocytic leukemia cell line 
cells treated with drug C1 50μg/ml and C1 0μg/ml as control for various time points for 
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three independent experiments. Each microarray hybridization used 20μg RNA of the 
sample and 20ug of common reference RNA that had been reverse transcribed to cDNA 
using amino allyl dUTP instead of dTTP. The common reference RNA was made by 
combining all the RNAs. The aminoallyl group in aminoallyl-modified nucleotides is 
reactive with dyes. The amine group in the aminoallyl moiety is aliphatic and thus more 
reactive compared to the amine groups that are directly attached to the rings (aromatic) of 
the bases and aminoallyl labelling of nucleotides renders them more reactive to the Cy3 
(green excitation peak 550nm and emission peak 570nm) and Cy5 (red excitation peak 
649nm and emission peak 670nm) dyes.  
After hybridization of the both cDNA (reference and sample) to the microarray chip the 
chip was scanned using the GenePix® 4000B scanner (Molecular Devices now MDS, 
Inc., Toronto, Canada) and image processing was performed using the GenePix Pro 4.0 
software. The scanner generates a 16 bit image so the range of the signal is from 1 to 
65536 (216). A cutoff value of 200 was randomly selected to diminish noise. The overall 
green and red intensities were equated and normalized to median 1 across chips. 
Microarray dataset was analysed using Genedata Expressionist Refiner (GeneData, 
Martinsried, Germany). Our analysis began with determining the chip quality based on 
image distortion, signal imbalance and magnitude of masked area. Data was filtered for 
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PART IV   RESULTS 
 
1.   Drug C1 causes non classical apoptosis in MCF-7 cells 
 
1.1   Drug C1 is selective to tumor cells 
 
The drug C1 is a small molecular weight lipophilic compound with the scientific name N, 
N’-Dibutyl-thio-4,5-imidazolindion (MW 242). Its structure comprises of an imidazole 
ring with two butyl side chains. It was originally generated by photoactivation of the 
lipophilic polymethine chromophore merocyanine 540 which generates a mixture of 
photoproducts (Gulliya et al., 1994), many of which upon isolation and purification have 
been found to be biologically active compounds (Gulliya et al., 1990; Pervaiz et al., 
1999).  
Since pMC540 is a mixture of photoproducts, our lab separated and purified the 
components to investigate the biological activity of the purified photoproducts and we 
narrowed down two of the fractions C1 and C2 which showed efficient induction of 
apoptosis in HL60 and M14 cell lines with largely similar caspase activation, however 
the two compounds differed in their ability to cause mitochondrial swelling and loss of 
transmembrane potential, while C1 caused a loss of transmembrane potential and 
swelling of isolated mitochondria, C2 does not. Both are however effective at inducing 
cytochrome c release from mitochondria (Pervaiz et al., 1999). 
The drug C1 has previously been reported by us to cause classical apoptosis with 
activation of caspases, translocation of cytc from the mitochondria to the cytosol, and a 
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drop in the transmembrane potential in leukemia cell line HL60 and melanoma cell line 
M14 (Pervaiz et al., 1999).  
In MCF-7 cells also with drug C1 we find that inhibition of proliferation occurs as 
assayed by the MTT assay (figure 1A), and MCF-7 cells show a dose response to drug 
C1 and the percentage cell survival at 18hrs compared to untreated cells with C1 25μg/ml 
is 85%, C1 50μg/ml is 65% and C1 100μg/ml is 35%. This is particularly relevant as a 
comparison of the drug response in the non tumorogenic cell line MCF10a shows cell 
survival percentage after a 18 hr treatment of 93%, 90% and 64% for the corresponding 
doses of C1. MCF10a is a non tumorigenic cell line of epithelial origin and does not 
cause tumor formation in immunosuppressed mice and can therefore be considered to 
resemble normal cells. Since the suppression of proliferation is much higher in the cancer 
cell line MCF-7 compared to MCF10a we can aver that drug C1 shows specificity to 
cancer cells. We went on to confirm our finding in HL60 cells human promyelocytic 
leukemia cells which is again a cancer cell line and in peripheral blood lymphocytes 
(PBL) which are the mature lymphocytes (small white immune cells) that are found 
circulating in the blood and are normal cells and can be considered as a normal analogue 
to HL60 cells. We find that in HL60 cells the percentage survival is 74% with C1 
25μg/ml, 49% with C1 50μg/ml and 12% with C1 100μg/ml. And the survival 
percentages when C1 treatment is administered in the case of PBLs is 99%, 87%, 76% 
for the corresponding doses. Thus we have been able to show that drug C1 is effective in 
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Figure 1. Effect of drug C1 on cell survival of various cell types: (A) MCF-7, MCF10a, 
HL60 cells and PBLs were incubated with drug C1 at various concentrations for 18hrs 
and cell viability was assayed by MTT assay. Percentage change in cell survival relative 
to untreated cells is plotted. Results are shown as mean of at least 3 independent 
experiments + SE. Comparisons were made using the two-tailed Student’s t test for 
sample with unequal variance ; * is p< 0.05. 


























1.2   Drug C1 causes phenotypic changes in MCF-7 cells 
 
MCF-7 cells treated with drug C1 were examined under the light microscope for obvious 
phenotypic alterations. At 25μg/ml dosage of C1 the cells were visually indistinguishable 
from control untreated cells upon a 18hr incubation and at 50μg/ml dosage we did start to 
see some phenotypic alteration with respect to the shape of the cells and there did seem to 
be a small population of cells which were smaller and had visibly a rounded appearance. 
Upon C1 100μg/ml treatment for 18 hrs we see very obvious shrinkage of the cells, a loss 
of contact with the neighbouring cells and rounding off of cells and there is a 
disadherence from the substratum pointing to a anoikis phenotype which is a form of 
apoptotic cell death response (figure 2A).  
 
1.3   MCF-7 cells show a dose response upon C1 treatment in a colony formation 
assay 
 
Colony formation assay or clonogenic assay is a method to determine the long term 
impact of a drug on the cells that are treated with the drug. While tests for cell viability, 
proliferation, cell death markers all deal with relatively short term effect of the drug on 
the cell, this clonogenic assay contributes to understanding the long term consequence on 
the viability of the cells as a result of the treatment with the drug for a certain period of 
time. It is particularly important to understand what impact the drug has after it has been 
‘washed off’ from the milieu of the cells which is how it may be predicted to be in vivo 
where various factors cause the elimination of the drug from the immediate environment. 
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The response of MCF-7 cells to drug C1 shows that at 25μg/ml of C1 or less there is no 
significant impact on the long term proliferation ability of the cell. This is relevant and 
surprising as the MTT assay shows a 15% decrease in cell survival, apparently removal 
of the medium containing the drug and subsequent replating can relieve the cells of the 
xenobiotic stress caused by the drug at these doses. However, at 50μg/ml dose of C1 
there is a perfect correlation between the cell survival percentage found by the MTT 
assay which is 65% and the colony formation assay which is 64% demonstrating that this 
dose is potent and has a lasting impact on the ability of the cells to survive. Also obvious 
from the result of the assay is that the C1 100μg/ml is a overwhelming dose and only 5% 
of the cells treated with C1 100μg/ml will be able to form colonies. This also reflects the 
dichotomy between the MTT assay and colony formation assay where the cell survival 
percentage by MTT assay upon C1 100μg/ml treatment is 35% and perhaps does not 
reflect the extreme lethality of this dose. C1 200μg/ml does not show any colonies at all. 
Also important is to note is the observation that the size of the colonies becomes smaller 
at the higher drug doses of 50μg/ml and upwards. 
 
1.4   Drug C1 induces caspase activation in MCF-7 cells 
 
Caspase activity has long been associated with apoptosis and extensive research into 
caspases has led to the understanding of the differences in the pathways adopted by 
various triggers to cause apoptosis. For instance the mitochondria may be central to the 
process of apoptosis and the permeabilization of the outer membrane of the mitochondria 
may lead to release of cytochrome c which interacts with APAF1 and caspase 9 forming 
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the apoptosome, or, alternately, the death receptors may trigger an alternate pathway 
involving caspase 8 which may subsequently also lead to the activation of the 
mitochondrial pathway. However to our surprise we found that neither caspase 8 nor 
caspase 9 were important in our system. Across time points from 4 hr to 18 hrs we found 
that caspase 2, caspase 6, caspase 8, caspase 9 showed no increase in activity at all at 
both the 50μg/ml and the 100μg/ml doses. However we did find an early and substantial 
increase in the activity of caspase 7 at the higher dose of 100μg/ml. More specifically we 
found a four fold increase in caspase 7 activity at the 4hr time point after which it 
gradually decreases.  
MCF-7 is a caspase 3 deficient cell line and has been known to show anomalous 
phenotypic changes, or rather the lack of familiar phenotypic changes including DNA 
degradation upon various apoptotic stimuli, however, bax translocation, PARP1 cleavage 
and cell death itself are unaffected by the paucity of caspase 3 (Kagawa et al., 2001). It is 
also seen that the apoptotic response may depend on the trigger, some triggers induce 
responses that are not inhibitable by pan caspase inhibitors like z-VAD, while others are, 
and this may depend on trigger and cell type, the authors found that caspase 3 is 
necessary for apoptosis following UV but not following gamma irradiation, and TNFα 
induced apoptosis was found to be caspase 3 dependant in oncogenically transformed 
MEFs and not in thymocytes (Woo et al., 1998).  Similarly the effect of staurosporine and 
TNF were found to have different levels of apoptosis in different cell lines which did not 
correlate with caspase 3 processing and activity. Caspase 3 activation may dependent not 
only on the death stimulus but also on the cell type (Janicke et al., 1998) 
 58
MCF-7 is a breast carcinoma cell line that has lost caspase 3 because of a 47 base pair 
deletion within exon 3 of the caspase 3 gene. This deletion results in the skipping of exon 
3 during pre-mRNA splicing, thereby abolishing the translation of the caspase 3 mRNA 
(Janicke et al., 1998). Caspase 3, caspase 6 and caspase 7 are highly homologous 
caspases and are known executioner caspases. Indeed, caspase 3 and caspase 7 share their 
substrate specificity and cleave their substrates after the DEVD motif (Asp-Glu-Val-
Asp).  
 While depletion of caspase 3 has many significant characteristics the abrogation of 
caspase 6 or caspase 7 have no effect. It has also been shown in a cell free system that 
while caspase3 may be the caspase important in cleavage of a majority of substrates, 
caspase 7 can redundantly cause the cleavage of some of the substrates (Slee et al., 2001). 
Caspase 7 is known to be important in cleavage of caspase 12 upon thapsigargin or 
brefeldin-A which are classical inducers of ER stress, which reflects upon the potential 
for a non redundant function of caspase 7 (Rao et al., 2001). Deficiency in caspase 3 is 
has been shown in hepatocytes to elicit compensatory activation of caspase 7, which was 
not detected in wild-type hepatocyte cells (Zheng et al., 2000) 
In C1 treated MCF-7 cells we find caspase 7 activation and we postulate that the 
deficiency of caspase 3 is compensated for here by caspase 7. However we note that there 
is no caspase 7 activation at the 50μg/ml dose of C1 even though at this dose there is 
significant decrease in cell survival. We explain this by the repeated observations in 
MCF-7 cells of a lack of the attributes of apoptosis in these cells. In M14 melanoma and 
HL60 promyelocytic leukemia cell line drug C1 has been shown to cause caspase 3 and 










Figure 2. Morphological and long term effects of drug C1 on MCF-7 cells (A) Light 
microscope image showing effect of drug C1 on MCF-7 cells at various concentrations 
upon 18hr treatment (B) Colony formation assay - MCF-7 cells were treated with C1 at 
various doses (0, 12.5, 25, 50, 100, 200μg/ml) for 18 hrs and then equal number of 
treated cells (2 x 104) were seeded and allowed to form colonies over 10-14 days. 
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Figure 3. Drug C1 increases Caspase 7 activity in MCF-7 cells upon high dose drug 
treatment: Caspase 7 activity was assayed after incubating MCF-7 cells with drug C1 at 
100μg/ml or 50μg/ml concentrations for various time points and the fold change in 
activity compared to activity of untreated cells at 1hr was plotted. Data represents mean 































































Figure 4. Drug C1 does not cause change in activity of Caspases 2, 6, 8, 9: Caspase 2, 7, 
6, 8, 9 activity was assayed after incubating MCF-7 cells with drug C1 at 100μg/ml or 
50μg/ml concentrations for various time points and the fold change in activity compared 
to activity of untreated cells at 4hrs was plotted. Data represents mean activity +/- SE of 




























































1.5   Drug C1 causes a drop in the transmembrane potential of MCF-7 cells 
 
Drug C1 has previously been shown to cause a drop in transmembrane potential in rat 
liver mitochondria concomitant with a pronounced swelling of the mitochondria and 
causes a drop in the transmembrane potential as observed by change in fluorescence of 
potential sensitive dye DiOC6 (Pervaiz et al., 1999). 
DiOC6 (dihexaoxacarbocyanine iodide) is a positively charged molecule that permeates 
through the plasma membrane. At low concentrations, it accumulates in mitochondria 
due to their large negative membrane potential. At higher concentrations, the dye stains 
other membranes, including the ER.  
We observe than in MCF-7 cells when the incubation is for 12 hrs with 25μg/ml of C1 
there is no perceptible shift in the G mean of the histogram for the DiOC6 fluorescence 
(figure 5A) indicating that there is no substantial change in the transmembrane potential. 
However upon 50μg/ml C1 treatment for 12 hrs there is an emergence of a population 
which has lower transmembrane potential. Also by 100μg/ml treatment for 12 hrs there is 
a perceptible shift of the G mean of the population indicating that there is a appreciable 
change in the transmembrane potential (figure 5A, 5C). Upon C1 25μg/ml treatment the 
G mean decreases by 22% compared to the untreated cells, upon C1 50μg/ml treatment it 
decreases further to 35% and upon C1 100μg/ml treatment it becomes 64% lower (figure 
5C). 
A study of the change in the density plot of the population plotted with forward scatter in 
the X axis and fluorescence in the green channel (PMT2) in the Y axis shows an increase 
in the lower left quadrant which is the region having the population of cells with low 
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transmembrane potential (figure 5B). More specifically, the bar graph reflects the fold 
change in the population of cells with low transmembrane potential as increasing by 1.8 
fold upon C1 25μg/ml treatment, 3.1 fold by 50μg/ml treatment and 5.3 fold by 100μg/ml 
treatment (figure 5D). This population of cells is also conspicuously smaller in size as 
reflected by their being in the left quadrant. 
This drop in transmembrane potential in MCF-7 cells has been described with other 
triggers which may or may not result in cell death (Essmann et al., 2004).  
Transmembrane potential in case of the 50μg/ml dose of C1 is not greatly impacted even 
though at this dose there is significant decrease in survival and there is cytochrome c 
release from the mitochodria into the cytosol. But some studies have shown that 
transmembrane potential can be maintained even when there is a release of cytochrome c 
as there is still sufficient amount of cytochrome c to maintain electron transport and 
transmembrane potential and ATP generation, and it has even been suggested that cells 
that initially undergo mitochondrial outer membrane permeabilisation may recover and 
proliferate if the caspase activity in the cell is blocked (Waterhouse et al., 2001). 
In the case of C1 50μg/ml dose in MCF-7 cells as there is no caspase activation at this 
dose we can postulate that there is an analogous situation with lack of caspase activity, 
outer membrane permeabilisation (as reflected by cytochrome c release at this dose and 















































































Figure 5. Transmembrane potential changes following C1 treatment in MCF-7 cells: (A) 
Transmembrane potential decrease was detected by staining with a potential sensitive 
probe (DiOC6) and flow cytometry analysis in MCF-7 cells upon C1 treatment at 12hrs. 
(B) The density plot shows variation of population cell size (Forward scatter) along X 
axis with membrane potential in the Y axis, a representative experiment from three 
independent experiments is shown. (C) Histogram represents percentage variation in G 
mean upon C1 treatment relative to untreated cells at12hrs. (D) Histogram represents fold 
increase in population of cells with low transmembrane potential, data in C, D represent 
the mean +/- SE of three independent experiments.   
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1.6 Analysis of cell cycle profile upon C1 drug treatment 
 
A study of the cell cycle profile is a reflection of the DNA content of the cells in the 
population, and consequently can mirror the effect on the cell cycle of added stimuli.  As 
the cell cycle of normal cells is characterized by a well defined peak corresponding to the 
cells in G1 phase of the cell cycle and a subsequent smaller and flatter peak corresponds 
to cells in G2/M phase of the cell cycle and in between the two peaks is the region 
corresponding to cells in the S phase of the cell cycle with between n and 2n amount of 
DNA. Any perturbances like inability to move to the next phase of the cell cycle due to 
drug or other treatment will clearly show up as deviations from the normal cell cycle 
profile. Also as apoptosis is characterized by degradation of DNA there is a clear increase 
in the sub G1 phase of the cell cycle in response to apoptosis 
Upon C1 treatment for 24 hrs the cell cycle profile was analyzed and it was surprising to 
find that even at the very overwhelming drug dose of 100μg/ml where the cells are 
visibly rounded and shrunk and survival is only 35% of the control there is no discernable 
DNA fragmentation (figure 6A, 6B). We therefore went on to analyze the cell cycle 
profile at 48hrs and 72hrs incubation with the drug and we found that there is an increase 
in the subG1 content (fragmented DNA content) at 48 hrs and even more so at 72hrs 
(figure 6A, 6C, 6D). So we conclude that apoptosis induced by C1 is unconventional and 
includes a delayed DNA fragmentation response. 
However in the MCF-7 breast carcinoma cell line such deviations from conventional 
apoptotic response are well documented. In response to taxol and staurosporine also 
MCF-7 cells show limited DNA fragmentation (Ofir et al., 2002), and it has also been 
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shown that replacement of the caspase 3 gene product restores the ability to show 
conventional apoptosis with DNA fragmentation (Kagawa et al., 2001). 
Further analysis of the cell cycle profile shows that at 24 hrs even though there is no 
fragmentation of DNA there is an arrest of the cell cycle in the G1 phase and in a less 
obvious manner in the G2/M phase (figure 6B). At all three doses of C1 (25μg/ml, 
50μg/ml, 100μg/ml) there is a visible increase in the G1 population (11%, 5% and 13% 
respectively) and of the G2/M population (7%, 15% and 10% respectively). This reflects 
that the drug C1 is inducing cell cycle arrest by invoking mitotic checkpoint proteins, like 
p53, ATM (ataxia telangiectasia mutated), and MAD (mitotic arrest deficient), and 
further work needs to be done in order to ascertain the proteins involved in C1 mediated 
arrest of the cell cycle at both G1 and G2/M phases. By 48 hrs these arrested cells roll 
over and probably cause the increase in population of cells with fragmented DNA as in 
the G1 and G2/M phases of the 48 hr profile the increase seen due to the arrest brought 
about by the drug is abrogated, and there is a concomitant increase in the subG1 
population (figure 6C). By 72 hrs there is a sharp decrease in the G1 and G2/M 
populations in the C1 50μg/ml and C1 100μg/ml treated samples and a concomitant 
















0 25 50 100
1% 1% 2% 6%






































































Figure 6. Cell cycle analysis of MCF-7 cells treated with drug C1 shows DNA 
degradation at 72hrs but not earlier (A) MCF-7 cells were incubated with drug C1 at 
various doses for 24, 48 and 72 hrs and stained with propidium iodide for cell cycle 
analysis by flow cytometry. Data shown is representative of three independent 
experiments. Marker represents proportion of cells with sub-G1 DNA content. (B,C,D) 
Histograms represent proportion of cells in different phases of cell cycle at 24hrs (B), 






1.7   C1 treatment causes release of apoptogenic factors from the mitochondria in 
MCF-7 cells 
 
Since the treatment of MCF-7 cells with drug C1 caused a change in the percentage 
survival as gauged by MTT assay in 18 hrs we went on to examine the effect it has on 
mitochondrial release of apoptogenic factors which is a well documented aspect of 
apoptotic cell death. Since we did not see a DNA fragmentation resulting from drug 
treatment we strived to understand the impact of drug C1 on the mitochondrial outer 
membrane permeabilization which leads to release of cytochrome c and AIF. Cytochrome 
c is an essential component of the respiratory chain, and upon release into the cytosol it 
forms with Apaf-1 and caspase 9 the ‘apoptosome’ in the prescence of ATP, which 
activates caspase 9 and consequently the downstream caspases. However we had found a 
lack of caspase 9 activity increase upon C1 treatment even at the high dose. But some 
studies have shown that even when there is a release of cytochrome c there is still 
sufficient amount of cytochrome c to maintain electron transport and transmembrane 
potential and ATP generation, and it has been suggested that cells that initially undergo 
mitochondrial outer membrane permeabilisation may recover and proliferate if the 
caspase activity in the cell is blocked (Waterhouse et al., 2001). However when there is 
extensive release of cytochrome c the cell reaches a point of no return and is a committed 
to apoptosis. It has even been shown that an addition of 10μM of cytochrome c 
extraneously can relieve the drop in transmembrane potential and the mitochondrial 
functions of ATP generation can be caused to resume (Waterhouse et al., 2001). We find 
the release of cytochrome c from the mitochondria into the cytosol as early as 6hrs when 
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treated with C1 100μg/ml (figure 7B). By 12 hrs the C1 50μg/ml and C1 100μg/ml both 
doses show cytochrome c release, which is much more in the higher dose (figure 7B). We 
can corroborate our transmembrane potential data and the cytochrome c release data as 
there is only partial release of cytochrome c at 12 hrs at the 50μg/ml dose and therefore 
the transmembrane potential loss is not significant. At the 100μg/ml dose at 12 hr 
treatment there is a extensive release of cytochrome c resulting in a significant drop in 
transmembrane potential. By 18 hrs there is significant cytochrome c release in both 
50μg/ml and 100μg/ml dosages of C1 (figure 7B). 
AIF the apoptosis inducing factor release from the mitochondria to the cytosol shows the 
same temporal kinetics as cytochrome c. At 6hrs there is release of AIF only at the 
100μg/ml dose of C1 and by 12 hrs AIF release is seen at both 50μg/ml and 100μg/ml 
doses. By 18 hrs again there is unequivocal release of AIF at the 50μg/ml and 100μg/ml 
doses (figure 7B).  
AIF is a particularly important factor in caspase independent cell death as it has been 
shown that even in the absence of caspase activity as would be the case where broad 
spectrum caspase inhibitors like zVAD-fmk are used AIF translocation to the nucleus and 
consequent PARP1 clevage is not affected (Yu et al., 2002). Although AIF is believed to 
translocate to the nucleus, interact with an endonuclease (as it does not possess intrinsic 
nuclease activity) and cause nuclear condensation and PARP1 clevage, it has been shown 
that AIF release occurs in a PARP1 dependant manner and when PARP1 inhibitors 1,5-
dihydroxyisoquinoline (DHIQ) or 3,4-dihydro-5-[4-(1-piperidinyl)butoxy]-1(2H)-
isoquinolinone (DPQ)  are used there is a consequent disruption of AIF release and 
translocation (Yu et al., 2002).  
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As we see AIF release and can see a parallel response of PARP1 we can postulate that in 
the C1 mediated apoptotic response we see AIF release and a concomitant PARP1 
activation. 
 
1.8   Bax translocation from cytosol to mitochondria 
 
Bax (Bcl-2-associated X protein) is a Bcl-2 family protein present in the cytosol and 
translocates to the mitochondria upon apoptotic stimuli where it heterodimerises with 
Bcl-2 at the BH1 and BH2 domains of Bcl-2 (Wolter et al., 1997; Yin et al., 1997; Yin et 
al., 1994). The Bax protein undergoes conformational changes that expose domains 
important in targeting to mitochondria. The disappearance of Bax from the cytosol and its 
concomitant increase in the mitochondria are hallmarks of the apoptotic phenotype, and 
we observe a disappearance of bax from the cytosol as early as 6hrs at the 100μg/ml 
dosage and at 12hrs at both C1 50μg/ml and 100μg/ml and by 18hrs there is again a 
distinct reduction of bax in the cytosolic fraction (figure 7B). These results are in 
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Figure 7. C1 drug treatment causes apoptotic response including PARP1 cleavage and 
translocation of apoptogenic factors to or from the mitochondria (A) MCF-7 cells were 
incubated with C1 at various concentrations for 6hrs, 12hrs or 18hrs and the whole cell 
lysates were probed with anti PARP1 antibody, GAPDH was used as loading control.  
(B) MCF-7 cells were treated with C1 drug at various doses for 6hrs, 12hrs or 18hrs and 
they were subjected to fractionation as described in materials and methods and the 
cytosolic fraction was immunoblotted for cytochrome c, AIF and Bax. CuZnSOD and 


























1.9   PARP1 clevage is observed with C1 treatment of MCF-7 cells 
 
PARP1 is Poly(ADP-ribose) polymerase-1 a nuclear enzyme that plays an essential role 
in responding to DNA damage by facilitating DNA repair. It is rapidly activated by DNA 
strand breaks and other apoptotic stimuli. Once activated, PARP1 transfers 50-200 
molecules of ADP ribose to several nuclear proteins including histones and PARP1 itself. 
Overactivation of PARP1 can lead to cell death, including CICD (Degterev and Yuan, 
2008). PARP1 mediated cell death is proposed  to be partly because of energy reduction 
resulting from using up of NAD+ reserves (Virag et al., 1998; Yu et al., 2002). PARP1 
may also be an important factor in the extrusion of AIF from the mitochondria as studies 
have shown AIF translocation to be PARP1 dependant (Yu et al., 2002). PARP1 is a 
116kDa protein which gets cleaved into a 89kDa and a smaller 25kDa products but the 
antibody used can only recognize the 89kDa fragment and the 116kDa full length protein 
so the western blot shows two bands when PARP1 is cleaved. We find a absolute 
correlation of PARP1 clevage with the other markers of the apoptotic response as at 6hrs 
we see PARP1 clevage at 100μg/ml dosage and we find that at 12hrs there is PARP1 
clevage at both C1 50μg/ml and C1 100μg/ml dosage and by 18hrs we observe PARP1 
clevage at 25μg/ml, 50μg/ml and 100μg/ml treatments and the amount of PARP1 clevage 







2.0   Microarray analysis of gene expression changes induced by C1 treatment on 
HL60 cells 
 
In order to understand the signal transduction involved in C1 drug response which causes 
apoptosis in HL60 human promyelocytic leukemia cells, M14 melanoma cells and human 
breast adenocarcinoma cell line MCF 7, we did a high throughput microarray experiment 
to look for genes that are differentially expressed upon C1 treatment in HL60 cells at 
various time points - 30 mins, 1hr, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs and 18 hrs. We were 
particularly interested in looking at the differential expression of genes in the early time 
points to be able to delineate transcription factors important in the early part of the signal 
transduction cascade initiated by the drug C1. The experimental set up consisted of 
control (untreated) and C1 50ug/ml treated HL60 cells that had been treated for time 
points ranging from 30 mins to 18hrs and whose RNA had been reverse transcribed to 
cDNA and subsequently labeled with Cy3 and the universal control (made by pooling all 
the cDNA) was labeled with Cy5 and the two (the sample and the universal control) were 
hybridized to a microarray chip that had been made in house using 18K cDNA targets.  
 
2.1   Analysis of chip quality 
 
Our analysis using the Genedata Expressionist Refiner software began with determining 
the chip quality based on image distortion, signal imbalance and magnitude of masked 
area. All but four of the microarray chips were considered of sufficient quality to 
continue processing. 
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2.2   Drug treated samples show greater variance than control samples 
 
The microarray data was characterized to look for across the board differences in 
variance using the one way ANOVA test between drug treated samples and control 
(untreated ) samples at various p values to examine if there is a increase in the number of 
genes which show change in the expression profile when treated with the drug. We see 
that at every p value there is a definite increase in variance in drug treated samples 
relative to untreated control samples. One-way analysis of variance (ANOVA) tests allow 
us to determine if one given factor, such as drug treatment, has a significant effect on 
gene expression behavior across any of the groups under study, here the groups are the 
expression levels at each time point 30mins, 1hr and so on. A significant p-value 
resulting from a 1-way ANOVA test would indicate that a gene is differentially expressed 
in at least one of the groups analyzed. If there are more than two groups being analyzed, 
however, the 1-way ANOVA does not specifically indicate which pair of groups exhibits 
statistical differences. As the results of the ANOVA test indicate in figure 8 that there are 
definitely more genes showing variance upon drug treatment than without, it confirms 
that there is an increase in the number of alterations in gene expression as a result of drug 
C1 50ug/ml treatment of HL60 cells. More specifically, there are 13 genes in the drug 
treated set that show variance at p value 0.005, while in the control set there are only 6. 
At p value 0.01 again there are more genes showing variance in the drug treated set (there 
are 36 genes) than in control set (11 genes), as p values become less stringent the number 
of genes swells up to 119 and 71 at p value of 0.05 and 222 and 141 genes at p value of 





































Figure 8. Analysis of variance test indicates that there is more changes in transcript 
levels in the drug treated samples than in control samples: Differences in variance 
between drug treated samples and control (untreated ) samples at various p values. Data 
for all time points are compiled for this analysis. One-way analysis of variance 











0.005 13 6 
0.01 36 11 
0.05 119 71 
0.1 222 141 
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 p=.005 p=.01 p=.05 p=0.1
30min 1 1 3 5
1 hr 3 7 20 39
2 hr 3 7 29 57
4 hr 4 9 39 80
8 hr 7 16 107 193
12 hr 17 29 127 197






Figure 9. t-test results show that there are more changes in transcript levels at later time 
points in C1 drug treated samples than in controls: Study of difference between the 
number of genes that differ in expression between drug treated and control cells at each 
time point using the t test at various p values.The geneset chosen for analysis was filtered 
by valid values as any data point that did not have a duplicate was not chosen for 






Table 1. Compilation of genes whose transcripts are upregulated at early time points upon C1 
treatment on HL60 cells  
 
GenBank  Symbol Annotation fold ch 
AI819173 NR4A3 nuclear receptor subfamily 4, group A, member 3 3.1 
AV758471 SCYA4 small inducible cytokine A4 (homologous to mouse Mip-1b) 1.9 
AA477581 NFATC1 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 
1 1.8 
AW978447 DLEU2 deleted in lymphocytic leukemia, 2 1.8 
BE729377 POLR2G polymerase (RNA) II (DNA directed) polypeptide G 1.8 
Z22576 CD69 CD69 antigen (p60, early T-cell activation antigen) 1.7 
AW272884 ETR101 immediate early protein 1.7 
AA575975 FDX1 ferredoxin 1 1.6 
U21108 DUSP4 dual specificity phosphatase 4 1.6 
AA600235 NEK6 NIMA (never in mitosis gene a)-related kinase 6 1.6 
H29054 VTN vitronectin (serum spreading factor, somatomedin B, complement S-protein) 1.6 
H62013 SCYA15 small inducible cytokine subfamily A (Cys-Cys), member 15 1.6 
M96684 PURA purine-rich element binding protein A 1.6 
AA644249 ALDH7A1 aldehyde dehydrogenase 7 family, member A1 1.6 
AB020650 KIAA0843 KIAA0843 protein 1.5 
AA126877 KCNE3 potassium voltage-gated channel, Isk-related family, member 3 1.5 
NM_005077 TLE1 transducin-like enhancer of split 1, homolog of Drosophila E(sp1) 1.5 
U73844 ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 1.5 
U90030 BICD1 Bicaudal D (Drosophila) homolog 1 1.5 
AI570435 RNF5 ring finger protein 5 1.5 
R88818 GSTM1 glutathione S-transferase M1 1.5 






Table 1. Compilation includes genes that are upregulated upon C1 treatment on HL60 
cells at time points 30 mins, 1hr or 2 hrs or in more than one time point. The genes are 
arranged in the decreasing order of fold change in expression relative to the untreated 
HL60 cells. Highlighted genes are known or potential transcription factors, tumor 






2.3   Gene expression variations at each timepoint between drug treated and control 
samples   
 
Additionally we looked at the difference between the number of genes that differ in 
expression between drug treated and control cells at each time point using the t test and 
we find that there is a much greater number of genes that change in expression at later 
time points like 8hrs, 12 hrs and 18 hrs. We attribute this pattern to the physiological 
response of the cell as we see clear evidence of cell death by 18 hrs. Also, as expected, at 
lower p values where the stringency is high the number of genes that show differential 
expression is comparatively less and as the stringency is decreased, the number of 
differentially expressed genes increases alongside the p value. The geneset chosen for 
analysis was filtered by valid values as any data point that did not have a duplicate was 
not chosen for analysis. The filtered gene set included 5968 items. Thus at 18 hrs there 
are 15 genes that are differentially expressed between control and treated samples at the 
p=0.005 significance level and 224 genes are differentially expressed at the p= 0.1 level 
of significance. 
 
The results of the microarray analysis for genes of interest upregulated in drug C1 
induced apoptotic conditions at early time points (30mins,1hr and 2hrs) as analysed by N 
fold regulation with a cut off at ≥1.5 fold are presented as table 1. 
Detailed lists with the genes that are overexpressed or underexpressed at each time point 
as analysed by N fold regulation with a cut off of ≥1.3 fold for the overexpression  and   
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≤ 0.8 fold for the underexpression at 30mins, 1hr, 2hr, 4hr, 6hr, 8hr, 12hr, 18hr are 
provided as tables 2 to 9. 
 
Genes upregulated at 30 mins : We find the upregulation of Ferridoxin 1 (FDX1) which 
is small iron-sulfur protein that transfers electrons from NADPH through ferredoxin 
reductase to a terminal cytochrome P450; dual specificity phosphatase 4 (DUSP4) DUSP 
4 inactivates and anchors MAP kinase family members like ERK2 which are associated 
with cellular proliferation and differentiation, and overexpression of DUSP4 prevented 
ERK2 activation (Caunt et al., 2008); NIMA (never in mitosis gene a)-related kinase 6 
(NEK6) is required for mitotic progression of human cells (Yin et al., 2003); vitronectin 
(VTN) is found in serum and tissues and promotes cell adhesion and spreading (Upton et 
al., 2008); chemokine (C-C motif) ligand 15 (SCYA15); potassium voltage gated 
channel, lsk related family, member 3 (KCNE3); transducin like enhancer of split 1 
(TLE1) which is a potential tumor suppressor and is involved in apoptosis and cell cycle 
regulation (Dayyani et al., 2008); early T cell activation actigen CD69; E74-like factor 3 
(ets domain transcription factor, epithelial specific) (ELF3) which has a  role as a 
transcription factor in inflammation, cartilage degeneration and suppression of repair 
(Peng et al., 2008); Bicaudal D (drosophila)homolog1 (BICD1) which has been 
implicated in membrane transport from the Golgi apparatus to the endoplasmic reticulum 
(Wanschers et al., 2007);  heterogeneous nuclear ribonucleoprotein A2/B1 (HNRPA2B1) 
which is a ubiquitously expressed heterogeneous nuclear ribonucleoproteins and is a 
RNA binding protein; megakaryoblastic leukemia (translocation) 1 (MKL1) which 
encodes a protein that interacts with the transcription factor myocardin (Morita et al., 
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2007); stromal antigen 1 (STAG1) STAG1 mRNA is induced in response to various 
genotoxic stresses in a p53-dependent manner (Anazawa et al., 2004); transmembrane 4 
superfamily member 4 (TM4SF4) - these proteins mediate signal transduction events that 
play a role in the regulation of cell development, activation, growth and motility 
(Berditchevski, 2001); transforming growth factor beta receptor III (betaglycan, 300kD) 
(TGFBR3) has functions including growth regulation, migration, apoptosis, and 
differentiation and is a important player in the TGF β (transforming growth factor β) 
induced cessation of proliferation and induction of apoptosis (Kirkbride et al., 2008); 
SMAD family member 5 (MADH5) is a transcription factor important in TGF β induced 
cessation of proliferation and apoptosis and is also involved in shear induced cell cycle 
arrest  (Chang et al., 2008); uromodulin (uromucoid, Tamm-Horsfall glycoprotein) 
(UMOD) which encodes the most abundant protein in urine; RAD1 (S. pombe) homolog 
(RAD1) which is part of a heterotrimeric cell cycle checkpoint complex (Guan et al., 
2007); serine/threonine kinase 24 (Ste20, yeast homolog) (STK24) which is important in 
oxidative stress-induced apoptosis of trophoblasts (Wu et al., 2008); protocadherin 18 
(PCDH18); aldehyde dehydrogenase 7 family, member A1 (ALDH7A1) encodes an 
enzyme that plays a major role in the detoxification of aldehydes generated by alcohol 
metabolism and lipid peroxidation (Mills et al., 2006) ; aldolase A, fructose-bisphosphate 
(ALDOA) which encodes a glycolytic enzyme; ATP-dependent RNA helicase (ROK1);  
eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2) ; WW domain binding 
protein 2 (WBP2) ; makorin, ring finger protein, 1 (MKRN1) ; EGF-like-domain, 
multiple 4 (EGFL4); NCK-associated protein 1 (NCKAP1) which is downregulated in 
alzheimer’s disease,  antisense oligo DNA of human NCKAP1 transcripts was found to 
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induce apoptosis of neuronal cells (Suzuki et al., 2000; Yamamoto et al., 2001); 6-
phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) which is important in 
regulation of cancer and forced expression of PFKFB3 protein activates glycolysis and 
promotes cell proliferation (Bando et al., 2005). 
Genes upregulated at one hour: We find the upregulation of various genes many of which 
are transcription factors including orphan nuclear receptor NR4A3, early T cell activation 
actigen CD69, ETR101 immediate early protein which is known to be upregulated on 
genotoxic stress (Burnichon et al., 2003). 
Genes upregulated at two hours: At 2hrs we again find upregulation of NR4A3 a nuclear 
receptor and transcription factor; and immediate early protein (ETR101) which is known 
to be upregulated on genotoxic stress (Burnichon et al., 2003); early T cell activation 
antigen CD69; and many more genes like small inducible cytokine A4 SCYA4 which is 
the chemokine (C-C motif) ligand 4; nuclear factor of activated T cells NFATC1, which 
is a  transcription factors and plays a central role in inducible gene transcription during 
immune response and T lymphocyte development (Koltsova et al., 2007) ; RNA 
polymerase11 polypeptide G (POLR2G) which encodes the seventh largest subunit of 
RNA polymerase II and may play a role in regulating polymerase function (Cojocaru et 
al., 2008); Aldehyde dehydrogenase 7 family member A1 (ALDH7A1) which plays a 
major role in the detoxification of aldehydes generated by alcohol metabolism and lipid 
peroxidation  ; glutathione S transferase M1 (GSTM1) which function in the 
detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, 
environmental toxins and products of oxidative stress by conjugation with glutathione ; 
nitric oxide synthase 1 neuronal (NOS1); YY1 transcription factor; BAI 1 associated 
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protein2 (BAIAP2); corticotrophin releasing hormone (CRH) which is secreted by the 
hypothalamus in response to stress (Lightman, 2008); sorbitol dehydrogenase (SORD); 
p53 binding protein TP53BP1 which is known to be important in DNA damage response 
(Anderson et al., 2001); neutral sphingomyelinase activation associated factor (NSMAF); 
phosphoribosyl pyrophosphate synthetase 2 (PRPS2); serine or cysteine proteinase 
inhibitor (SERPINH2) which is a heat shock protein; mitogen activated protein kinase 
kinase1 interacting protein (MAP2K1IP1); macrophage scavenger receptor 1 (MSR1). 
 
Many of these genes are known to be associated with regulation of cell cycle through 
interactions with transcription factors, while others are known to be regulated by stress 
related factors. 
Of the genes upregulated in the 30mins 1hr and 2 hr time points we find many 
transcription factors involved in impeding the cell cycle like NR4A3, ELF3, SMAD5 and 
YY1 
We find phosphatases and kinases important in regulating the cessation of the cell cycle 
like DUSP4, NEK6, STK24 
Potential/known tumor suppressors like TLE1, TGFBR3,  
Genes known to be expressed in response to genotoxic stress like STAG1, CRH 
Or constituents of known checkpoint complexes like RAD1, TP53BP1 




Genes downregulated at 30 mins : Downregulation of thyroid hormone receptor 
coactivating protein (SMAP) which is believed to be a nuclear receptor coactivator 
(Monden et al., 1999);  PKC iota (PRKC1) a kinase important in motility and invasion in 
glioblastoma multiforme ; a decrease in PKC iota which is known to result in a decrease 
in cell motility and invasion (Baldwin et al., 2008) ; small inducible cytokine A4 
(homologous to mouse Mip-1b) (SCYA4); E2F transcription factor 5, p130-binding 
(E2F5) which is an important transcription factor controlling cell cycle (Chen et al., 
2008; Swetloff and Ferretti, 2005); peptidylprolyl isomerase C (cyclophilin C) (PPIC), 
zinc/iron regulated transporter-like (ZIRTL) 
Genes downregulated at one hour : Downregulation of NCK associated protein 
1(NCKAP1) which is downregulated in alzheimer’s disease and suppression of NCKAP1 
induces apoptosis (Suzuki et al., 2000; Yamamoto et al., 2001); histone deacetylase5 
(HDAC5) which represses transcription of cyclin D3 (Roy et al., 2008); small inducible 
cytokine subfamily A member 15 (SCYA15); histone acetyltransferase (MORF) which 
associates with histone acetlytransferases and deacetylases and are associated with 
transcription activation (Pena and Pereira-Smith, 2007); RAD1 homolog, the RAD1 gene 
of Saccharomyces cerevisiae is required for nucleotide excision repair and also acts in 
mitotic recombination (Saparbaev et al., 1996);   
Genes downregulated at two hours : At 2hrs there is downregulation of B cell 
CLL/lymphoma 7B (BCL7B); zinc finger protein 266 (ZNF266); ubiquitin specific 
protease 19 (USP19); granulin (GRN); phosphatidylinositol-4-phosphate 5-kinase, type I, 
alpha (PIP5K1A); transcription factor E2F3 which is overexpressed in many cancers and 
is important in controlling cell cycle progression (Cooper et al., 2006). 
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Downregulation of genes whose products result in stimulation of the cell cycle and 
transcription factors associated with cell proliferation are seen as anticipated. 
Downregulation of coactivators of nuclear receptors like SMAP,  
kinases like PKC iota,  
downregulation of transcription factors important in progression of the cell cycle like 
E2F5 and E2F3,  
downregulation of NCKAP1 gene transcript which leads to apoptosis in neuronal cells by 
mechanisms not fully understood are all reflecting the many pronged signal transduction 






























Table 2. Genes overexpressed and underexpressed at 30 mins time point  
 
genes overexpressed at 30mins  
    
GenBank  Symbol  Annotation  
fold 
ch 
AA575975 FDX1 ferredoxin 1 1.6 
U21108 DUSP4 dual specificity phosphatase 4 1.6 
AA600235 NEK6 NIMA (never in mitosis gene a)-related kinase 6 1.6 
H29054 VTN 
vitronectin (serum spreading factor, somatomedin B, 
complement S-protein) 1.6 
H62013 SCYA15 small inducible cytokine subfamily A (Cys-Cys), member 15 1.6 
AB020650 KIAA0843 KIAA0843 protein 1.5 
AI222413 - EST 1.5 
AA126877 KCNE3 potassium voltage-gated channel, Isk-related family, member 3 1.5 
NM_005077 TLE1 transducin-like enhancer of split 1, homolog of Drosophila E(sp1) 1.5 
Z22576 CD69 "CD69 antigen (p60, early T-cell activation antigen)" 1.5 
U73844 ELF3 
"E74-like factor 3 (ets domain transcription factor, epithelial-
specific )" 1.5 
U90030 BICD1 Bicaudal D (Drosophila) homolog 1 1.5 
AK001927 FLJ10462 hypothetical protein FLJ10462 1.4 
D28877 HNRPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 1.4 
AI131342 - 
"ESTs, Highly similar to A43542 lymphocyte-specific protein 1 
[H.sapiens]" 1.4 
AI365472 MKL1 megakaryoblastic leukemia (translocation) 1 1.4 
AA828552 STAG1 stromal antigen 1 1.4 
AA534229 - Human clone 23614 mRNA sequence 1.4 
AI337361 TM4SF4 transmembrane 4 superfamily member 4 1.4 
H29238 KIAA0095 KIAA0095 gene product 1.4 
AA173890 TGFBR3 
"transforming growth factor, beta receptor III (betaglycan, 
300kD)" 1.4 
AI796794 - ESTs 1.4 
BE672508 - 
"Homo sapiens cDNA: FLJ21927 fis, clone HEP04178, highly 
similar to HSU90909 Human clone 23722 mRNA sequence" 1.4 
AF010601 MADH5 
"MAD (mothers against decapentaplegic, Drosophila) homolog 
5" 1.4 
M15881 UMOD "uromodulin (uromucoid, Tamm-Horsfall glycoprotein)" 1.4 
AI127871 - "EST, Moderately similar to MIFR-1 [H.sapiens]" 1.4 
H39212 - "ESTs, Weakly similar to PN0099 son3 protein [H.sapiens]" 1.3 
H51180 FLJ20847 hypothetical protein FLJ20847 1.3 
AI474618 RAD1 RAD1 (S. pombe) homolog 1.3 
BF089707 STK24 "serine/threonine kinase 24 (Ste20, yeast homolog)" 1.3 
AI583132 BM-002 hypothetical protein 1.3 
AA604083 PCDH18 protocadherin 18 1.3 
AA644249 ALDH7A1 "aldehyde dehydrogenase 7 family, member A1" 1.3 
AI055850 - EST 1.3 
AI094575 - EST 1.3 
H43206 ALDOA "aldolase A, fructose-bisphosphate" 1.3 
AK025721 ROK1 ATP-dependent RNA helicase 1.3 
R72597 - ESTs 1.3 
AL117412 EIF4A2 "eukaryotic translation initiation factor 4A, isoform 2" 1.3 
AI057233 - ESTs 1.3 
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T71990 WBP2 WW domain binding protein 2 1.3 
AA054341 FLJ10342 hypothetical protein FLJ10342 1.3 
AF117233 MKRN1 "makorin, ring finger protein, 1" 1.3 
R95927 - ESTs 1.3 
AA600944 KIAA1624 KIAA1624 protein 1.3 
H06615 - 
"ESTs, Moderately similar to T43492 hypothetical protein 
DKFZp434A219.1 [H.sapiens]" 1.3 
AI637578 - ESTs 1.3 
H60560 - "Homo sapiens cDNA FLJ11562 fis, clone HEMBA1003197" 1.3 
AI024631 - 
"ESTs, Moderately similar to ALU5_HUMAN ALU SUBFAMILY 
SC SEQUENCE CONTAMINATION WARNING ENTRY 
[H.sapiens]" 1.3 
AA017080 MGC3035 hypothetical protein MGC3035 1.3 
AV751780 EGFL4 "EGF-like-domain, multiple 4" 1.3 
AW103454 FLJ21079 hypothetical protein FLJ21079 1.3 
AB018264 KIAA0721 KIAA0721 protein 1.3 
AA580371 NCKAP1 NCK-associated protein 1 1.3 
N23313 PFKFB3 "6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3" 1.3 
    
genes underexpressed at 30 mins  
    
AA570746 SMAP thyroid hormone receptor coactivating protein 0.7 
T57875 PRKCI "protein kinase C, iota" 0.7 
AV758471 SCYA4 small inducible cytokine A4 (homologous to mouse Mip-1b) 0.7 
AI469189 E2F5 "E2F transcription factor 5, p130-binding" 0.7 
AA043412 PPIC peptidylprolyl isomerase C (cyclophilin C) 0.7 
AI279943 - EST 0.7 























Table 3. Genes overexpressed and underexpressed at 1hr time point 
 
genes overexpressed at 1hr  
    
GenBank  Symbol Annotation 
fold 
ch 
AI819173 NR4A3 "nuclear receptor subfamily 4, group A, member 3" 3.1
Z22576 CD69 "CD69 antigen (p60, early T-cell activation antigen)" 1.7
AW272884 ETR101 immediate early protein 1.7
R85387 - "Homo sapiens cDNA: FLJ23313 fis, clone HEP11919" 1.4
AI139145 MGC11314 hypothetical protein MGC11314 1.4
R39858 - ESTs 1.4
BE408368 FLJ14451 hypothetical protein FLJ14451 1.4
    
1hr underexpressed genes   
    
AA558494 MGC3279 hypothetical protein MGC3279 similar to collectins 0.6
AA132065 AF140225 hypothetical protein AF140225 0.6
AA580371 NCKAP1 NCK-associated protein 1 0.7
AA593835 FLJ20494 similar to mouse neuronal protein 15.6 0.7
AA551124 - "Homo sapiens cDNA FLJ12825 fis, clone NT2RP2002800" 0.7
AA617796 HDAC5 histone deacetylase 5 0.7
H62013 SCYA15 "small inducible cytokine subfamily A (Cys-Cys), member 15" 0.7
AA057313 MORF histone acetyltransferase 0.7
AI474618 RAD1 RAD1 (S. pombe) homolog 0.7
AA021432 LOC51012 CGI-107 protein 0.7
BE672508 - 
"Homo sapiens cDNA: FLJ21927 fis, clone HEP04178, highly 
similar to HSU90909 Human clone 23722 mRNA sequence" 0.7
H46950 - ESTs 0.7
AA054341 FLJ10342 hypothetical protein FLJ10342 0.7




















Table 4. Genes overexpressed and underexpressed at 2hr time point 
 
2hr overexpressed genes  
    
GenBank  Symbol Annotation 
fold 
ch 
AI819173 NR4A3 "nuclear receptor subfamily 4, group A, member 3" 3.4 
AI796794 - ESTs 2.4 
AL390184 LOC58525 
hypothetical protein DKFZp547M136 similar to widely-interspaced 
zinc finger motifs 2.3 
AI024631 - 
"ESTs, Moderately similar to ALU5_HUMAN ALU SUBFAMILY 
SC SEQUENCE CONTAMINATION WARNING ENTRY 
[H.sapiens]" 2.0 
AV758471 SCYA4 small inducible cytokine A4 (homologous to mouse Mip-1b) 1.9 
AA477581 NFATC1 
"nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 1" 1.8 
AW978447 DLEU2 "deleted in lymphocytic leukemia, 2" 1.8 
BE729377 POLR2G polymerase (RNA) II (DNA directed) polypeptide G 1.8 
AI094575 - EST 1.8 
BF196945 - ESTs 1.8 
AA971955 -   1.7 
M96684 PURA purine-rich element binding protein A 1.6 
AW103454 FLJ21079 hypothetical protein FLJ21079 1.6 
AA644249 ALDH7A1 "aldehyde dehydrogenase 7 family, member A1" 1.6 
AA258394 - TCR eta 1.6 
AI570435 RNF5 ring finger protein 5 1.5 
R88818 GSTM1 glutathione S-transferase M1 1.5 
U17327 NOS1 nitric oxide synthase 1 (neuronal) 1.5 
AW272884 ETR101 immediate early protein 1.5 
Z22576 CD69 "CD69 antigen (p60, early T-cell activation antigen)" 1.5 
AA534229 - Human clone 23614 mRNA sequence 1.5 
AB015020 BAIAP2 BAI1-associated protein 2 1.4 
AA824326 YY1 YY1 transcription factor 1.4 
AI200858 - EST 1.4 
BE326327 - ESTs 1.4 
BE045743 - "ESTs, Highly similar to AF198489 1 LBP-32 [H.sapiens]" 1.4 
AW513134 CRH corticotropin releasing hormone 1.4 
AI139145 MGC11314 hypothetical protein MGC11314 1.4 
L29008 SORD sorbitol dehydrogenase 1.4 
AW627377 - 
"ESTs, Highly similar to T12528 hypothetical protein 
DKFZp434N093.1 [H.sapiens]" 1.4 
AI824983 BLu BLu protein 1.4 
AA923451 KIAA1464 KIAA1464 protein 1.4 
AF078776 TP53BP1 "tumor protein p53-binding protein, 1" 1.4 
AI055850 - EST 1.4 
AI073488 - EST 1.3 
AI123926 - ESTs 1.3 
BF111145 NSMAF neutral sphingomyelinase (N-SMase) activation associated factor 1.3 
AI122714 - ESTs 1.3 
NM_002765 PRPS2 phosphoribosyl pyrophosphate synthetase 2 1.3 
NM_000505 F12 coagulation factor XII (Hageman factor) 1.3 
 89
AA772319 FLJ21031 hypothetical protein FLJ21031 1.3 
BE892678 SILV silver (mouse homolog) like 1.3 
R06762 SERPINH2 
"serine (or cysteine) proteinase inhibitor, clade H (heat shock 
protein 47), member 2" 1.3 
AA593835 FLJ20494 similar to mouse neuronal protein 15.6 1.3 
AI192520 - ESTs 1.3 
AI126178 - 
"EST, Weakly similar to Z195_HUMAN ZINC FINGER PROTEIN 
195 [H.sapiens]" 1.3 
AB018264 KIAA0721 KIAA0721 protein 1.3 
NM_004482 GALNT3 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (GalNAc-T3) 1.3 
AI201758 - ESTs 1.3 
AI079954 - 
"Homo sapiens cDNA: FLJ22281 fis, clone HRC03849, highly 
similar to S69002 human mRNA for AML1-EVI-1" 1.3 
AF117233 MKRN1 "makorin, ring finger protein, 1" 1.3 
AI095078 - ESTs 1.3 
AI362596 KIAA0229 KIAA0229 protein 1.3 
AI203421 - ESTs 1.3 
BE744310 FDPS 
"farnesyl diphosphate synthase (farnesyl pyrophosphate 
synthetase, dimethylallyltranstransferase, 
geranyltranstransferase)" 1.3 
AI251872 MAP2K1IP1 mitogen-activated protein kinase kinase 1 interacting protein 1 1.3 
D13264 MSR1 macrophage scavenger receptor 1 1.3 
H73577 MGC1127 hypothetical gene MGC1127 1.3 
AB020650 KIAA0843 KIAA0843 protein 1.3 
    
2hr underexpressed genes  
    
BE622365 BCL7B B-cell CLL/lymphoma 7B 0.4 
X78924 ZNF266 zinc finger protein 266 0.6 
R18439 USP19 ubiquitin specific protease 19 0.7 
AF055008 GRN granulin 0.7 
H22448 - ESTs 0.7 
R99600 - 
"ESTs, Highly similar to A57291 cytokine inducible nuclear protein 
C193 [H.sapiens]" 0.7 
U78575 PIP5K1A "phosphatidylinositol-4-phosphate 5-kinase, type I, alpha" 0.7 
AA180358 - ESTs 0.7 
R98770 - ESTs 0.7 
M16974 C8A "complement component 8, alpha polypeptide" 0.7 
H46950 - ESTs 0.7 
AI191275 - 
"Homo sapiens, clone MGC:9913 IMAGE:3870821, mRNA, 
complete cds" 0.7 
R39858 - ESTs 0.7 
AA148685 - 
"ESTs, Weakly similar to JC5256 adipocyte transcription factor, 
AEBP1 [H.sapiens]" 0.7 
AI074562 - EST 0.7 







Table 5. Genes overexpressed and underexpressed at 4hr time point 
 
genes overexpressed at 4hrs  
    
GenBank Symbol  Annotation  
fold 
ch 
R18439 USP19 ubiquitin specific protease 19 1.5 
R60338 - "Homo sapiens cDNA FLJ14609 fis, clone NT2RP1000944" 1.5 
AA570469 AP2A2 "adaptor-related protein complex 2, alpha 2 subunit" 1.4 
AA604681 LOC55924 hypothetical protein 1.4 
AF067420 - "Homo sapiens SNC73 protein (SNC73) mRNA, complete cds" 1.4 
AI453699 DIA1 diaphorase (NADH) (cytochrome b-5 reductase) 1.4 
BF185645 MRPL33 mitochondrial ribosomal protein L33 1.3 
AA575975 FDX1 ferredoxin 1 1.3 
AB011144 MCM3AP 
minichromosome maintenance deficient (S. cerevisiae) 3-
associated protein 1.3 
AI203421 - ESTs 1.3 
AK025721 ROK1 ATP-dependent RNA helicase 1.3 
AA054341 FLJ10342 hypothetical protein FLJ10342 1.3 
AA995008 E2F3 E2F transcription factor 3 1.3 
R54426 - 
"ESTs, Weakly similar to T17210 hypothetical protein 
DKFZp434N041.1 [H.sapiens]" 1.3 
R59777 ME3 "malic enzyme 3, NADP(+)-dependent, mitochondrial" 1.3 
H80842 - ESTs 1.3 
T74327 STAU "staufen (Drosophila, RNA-binding protein)" 1.3 
AI740449 KRAS2 v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog 1.3 
    
genes underexpressed at 4hrs  
    
R12098 - ESTs 0.7 
H43206 ALDOA "aldolase A, fructose-bisphosphate" 0.7 
AI365472 MKL1 megakaryoblastic leukemia (translocation) 1 0.7 
AA487145 FLJ13052 NAD kinase 0.7 
X93996 MLLT7 
"myeloid/lymphoid or mixed-lineage leukemia (trithorax 
(Drosophila) homolog); translocated to, 7" 0.7 
AA872570 FLJ21156 hypothetical protein FLJ21156 0.7 
AW103454 FLJ21079 hypothetical protein FLJ21079 0.7 
AV758471 SCYA4 small inducible cytokine A4 (homologous to mouse Mip-1b) 0.7 
D87989 UGTREL1 UDP-galactose transporter related 0.7 
AI609152 - 
"ESTs, Weakly similar to A40465 alanine transaminase 
[H.sapiens]" 0.7 
R66350 UCH37 ubiquitin C-terminal hydrolase UCH37 0.7 
U80735 PAXIP1L PAX transcription activation domain interacting protein 1 like 0.7 
AB037856 KIAA1435 KIAA1435 protein 0.7 
R18651 - ESTs 0.7 
NM_001379 DNMT1 DNA (cytosine-5-)-methyltransferase 1 0.7 
AK001817 FLJ10955 hypothetical protein FLJ10955 0.7 
R99600 - 
"ESTs, Highly similar to A57291 cytokine inducible nuclear protein 
C193 [H.sapiens]" 0.7 
BF683408 EIF3S9 "eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD)" 0.7 
 
 91
Table 6. Genes overexpressed and underexpressed at 6hr time point 
 
genes overexpressed at 6hrs  
    
GenBank  Symbol  Annotation 
fold 
ch 
AB015020 BAIAP2 BAI1-associated protein 2 2.1 
R19539 - ESTs 1.9 
AI911758 HLA-DRA "major histocompatibility complex, class II, DR alpha" 1.8 
AI193793 TNFRSF14 
"tumor necrosis factor receptor superfamily, member 14 
(herpesvirus entry mediator)" 1.6 
R44078 MKLN1 "muskelin 1, intracellular mediator containing kelch motifs" 1.6 
AA058669 - 
"ESTs, Weakly similar to MGB4_HUMAN MELANOMA-
ASSOCIATED ANTIGEN B4 [H.sapiens]" 1.6 
BF002799 PDGFC platelet derived growth factor C 1.6 
AA534229 - Human clone 23614 mRNA sequence 1.5 
AA021432 LOC51012 CGI-107 protein 1.5 
AA548229 - "Homo sapiens cDNA: FLJ22446 fis, clone HRC09457" 1.5 
AA644249 ALDH7A1 "aldehyde dehydrogenase 7 family, member A1" 1.5 
AI469122 KIAA0026 MORF-related gene X 1.4 
N25676 RAB6A "RAB6A, member RAS oncogene family" 1.4 
AI796794 - ESTs 1.4 
AI689395 FLJ22318 hypothetical protein FLJ22318 1.4 
AI243164 MTMR2 myotubularin related protein 2 1.4 
D87989 UGTREL1 UDP-galactose transporter related 1.4 
T50661 - "ESTs, Moderately similar to A26null allele [H.sapiens]" 1.4 
AW103454 FLJ21079 hypothetical protein FLJ21079 1.4 
BE694068 YWHAZ 
"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide" 1.3 
AI024631 - 
"ESTs, Moderately similar to ALU5_HUMAN ALU SUBFAMILY SC 
SEQUENCE CONTAMINATION WARNING ENTRY [H.sapiens]" 1.3 
AA599820 
UMP-
CMPK UMP-CMP kinase 1.3 
AB018264 KIAA0721 KIAA0721 protein 1.3 
AI079954 - 
"Homo sapiens cDNA: FLJ22281 fis, clone HRC03849, highly 
similar to S69002 human mRNA for AML1-EVI-1" 1.3 
M97370 ADORA2A adenosine A2a receptor 1.3 
BF196945 - ESTs 1.3 
M15881 UMOD "uromodulin (uromucoid, Tamm-Horsfall glycoprotein)" 1.3 
AB020650 KIAA0843 KIAA0843 protein 1.3 
BE409260 RPS15 ribosomal protein S15 1.3 
R59138 - ESTs 1.3 
U80735 PAXIP1L PAX transcription activation domain interacting protein 1 like 1.3 
AU131650 PDK1 "pyruvate dehydrogenase kinase, isoenzyme 1" 1.3 
AI088421 CLTB "clathrin, light polypeptide (Lcb)" 1.3 
NM_00290
4 RDBP RD RNA-binding protein 1.3 
AA521200 C1orf24 chromosome 1 open reading frame 24 1.3 
AI351491 OSBP oxysterol binding protein 1.3 
genes underexpressed at 6hrs  
    
AA570746 SMAP thyroid hormone receptor coactivating protein 0.6 
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AA533154 KIAA1463 KIAA1463 protein 0.6 
AV743379 SLC25A5 
"solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 5" 0.6 
AA877289 GIT1 G protein-coupled receptor kinase-interactor 1 0.7 
AA631338 - ESTs 0.7 
R98770 - ESTs 0.7 
H70488 HAO1 hydroxyacid oxidase (glycolate oxidase) 1 0.7 
BE798151 GNL1 guanine nucleotide binding protein-like 1 0.7 
AA557551 AF093680 similar to mouse Glt3 or D. malanogaster transcription factor IIB 0.7 
AA148480 FMO5 flavin containing monooxygenase 5 0.7 
BE622365 BCL7B B-cell CLL/lymphoma 7B 0.7 
AI538453 MYC v-myc avian myelocytomatosis viral oncogene homolog 0.7 
AI560204 MGC4767 hypothetical protein MGC4767 0.7 
AA946887 ZNF75 zinc finger protein 75 (D8C6) 0.7 
AU124962 MCM7 minichromosome maintenance deficient (S. cerevisiae) 7 0.7 
AI208131 FLJ23121 hypothetical protein FLJ23121 0.7 
X93996 MLLT7 
"myeloid/lymphoid or mixed-lineage leukemia (trithorax 
(Drosophila) homolog); translocated to, 7" 0.7 
R84261 P63 
"transmembrane protein (63kD), endoplasmic reticulum/Golgi 































Table 7. Genes overexpressed and underexpressed at 8hr time point 
 
genes overexpressed at 8hrs  
    
GenBank Symbol Annotation  
fold 
ch 
R00224 - "Homo sapiens, clone IMAGE:3952677, mRNA, partial cds" 1.5 
N25676 RAB6A "RAB6A, member RAS oncogene family" 1.5 
AW272884 ETR101 immediate early protein 1.5 
AI003568 MGC11034 hypothetical protein MGC11034 1.4 
U73844 ELF3 
"E74-like factor 3 (ets domain transcription factor, epithelial-
specific )" 1.4 
AA555216 AREG amphiregulin (schwannoma-derived growth factor) 1.4 
AF226684 PREB prolactin regulatory element binding 1.4 
AI218940 - ESTs 1.4 
AA558591 - 
"ESTs, Weakly similar to S59501 interferon receptor JFNAR 2-1 
[H.sapiens]" 1.4 
R96020 KIAA0416 KIAA0416 protein 1.4 
R52460 LOC51696 hHDC for homolog of Drosophila headcase 1.3 
AI184515 COX8 cytochrome c oxidase subunit VIII 1.3 
NM_000237 LPL lipoprotein lipase 1.3 
AA147461 - ESTs 1.3 
T52325 TES testis derived transcript (3 LIM domains) 1.3 
AW027443 SEC3 Sec3-like 1.3 
AI817486 ORC6L "origin recognition complex, subunit 6 (yeast homolog)-like" 1.3 
AI245283 - 
"Homo sapiens, clone MGC:16057 IMAGE:3613956, mRNA, 
complete cds" 1.3 
M15881 UMOD "uromodulin (uromucoid, Tamm-Horsfall glycoprotein)" 1.3 
H39212 - "ESTs, Weakly similar to PN0099 son3 protein [H.sapiens]" 1.3 
AA617796 HDAC5 histone deacetylase 5 1.3 
AI538453 MYC v-myc avian myelocytomatosis viral oncogene homolog 1.3 
AB020650 KIAA0843 KIAA0843 protein 1.3 
AA570469 AP2A2 "adaptor-related protein complex 2, alpha 2 subunit" 1.3 
AI024631 - 
"ESTs, Moderately similar to ALU5_HUMAN ALU SUBFAMILY 
SC SEQUENCE CONTAMINATION WARNING ENTRY 
[H.sapiens]" 1.3 
AA548229 - "Homo sapiens cDNA: FLJ22446 fis, clone HRC09457" 1.3 
AA604681 LOC55924 hypothetical protein 1.3 
    
genes underexpressed at 8hrs  
    
R59138 - ESTs 0.5 
R56598 TU12B1-TY TU12B1-TY protein 0.5 
R19539 - ESTs 0.5 
R38613 - ESTs 0.6 
BE622365 BCL7B B-cell CLL/lymphoma 7B 0.6 
R44078 MKLN1 "muskelin 1, intracellular mediator containing kelch motifs" 0.6 
N68447 - ESTs 0.6 
R59777 ME3 "malic enzyme 3, NADP(+)-dependent, mitochondrial" 0.7 
R52970 - ESTs 0.7 
AW978447 DLEU2 "deleted in lymphocytic leukemia, 2" 0.7 
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BF683408 EIF3S9 "eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD)" 0.7 
AI094575 - EST 0.7 
R06762 SERPINH2 
"serine (or cysteine) proteinase inhibitor, clade H (heat shock 
protein 47), member 2" 0.7 
NM_005035 POLRMT polymerase (RNA) mitochondrial (DNA directed) 0.7 
H60423 SLC17A2 "solute carrier family 17 (sodium phosphate), member 2" 0.7 
H80842 - ESTs 0.7 
H17618 - ESTs 0.7 
U17327 NOS1 nitric oxide synthase 1 (neuronal) 0.7 
R54426 - 
"ESTs, Weakly similar to T17210 hypothetical protein 
DKFZp434N041.1 [H.sapiens]" 0.7 
AA600944 KIAA1624 KIAA1624 protein 0.7 
BE408368 FLJ14451 hypothetical protein FLJ14451 0.7 
AV743379 SLC25A5 
"solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 5" 0.7 
AK001817 FLJ10955 hypothetical protein FLJ10955 0.7 
H18646 FLJ10697 hypothetical protein FLJ10697 0.7 
AI037879 FLJ10292 hypothetical protein FLJ10292 0.7 
H22448 - ESTs 0.7 
AA568660 LOC51057 hypothetical protein 0.7 
R51859 - ESTs 0.7 
AI358609 NIF3L1 "NIF3 (Ngg1 interacting factor 3, S.pombe homolog)-like 1" 0.7 
D28877 HNRPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 0.7 
AI055850 - EST 0.7 
H70488 HAO1 hydroxyacid oxidase (glycolate oxidase) 1 0.7 

























Table 8. Genes overexpressed and underexpressed at 12hr time point 
 
genes overexpressed at 12hrs  
    
GenBank Symbol Annotation  
fold 
ch 
AA057313 MORF histone acetyltransferase 3.3 
AA570469 AP2A2 "adaptor-related protein complex 2, alpha 2 subunit" 3.0 
AA551124 - "Homo sapiens cDNA FLJ12825 fis, clone NT2RP2002800" 2.6 
AA021432 LOC51012 CGI-107 protein 2.6 
AA054341 FLJ10342 hypothetical protein FLJ10342 2.3 
AW027443 SEC3 Sec3-like 2.3 
H39212 - "ESTs, Weakly similar to PN0099 son3 protein [H.sapiens]" 2.3 
R44078 MKLN1 "muskelin 1, intracellular mediator containing kelch motifs" 2.1 
AA147461 - ESTs 2.1 
AA553499 PDCD6IP programmed cell death 6-interacting protein 2.1 
AA558494 MGC3279 hypothetical protein MGC3279 similar to collectins 2.0 
AA555216 AREG amphiregulin (schwannoma-derived growth factor) 1.9 
AI538453 MYC v-myc avian myelocytomatosis viral oncogene homolog 1.9 
AA617796 HDAC5 histone deacetylase 5 1.8 
AA548229 - "Homo sapiens cDNA: FLJ22446 fis, clone HRC09457" 1.7 
AA593835 FLJ20494 similar to mouse neuronal protein 15.6 1.7 
AA558591 - 
"ESTs, Weakly similar to S59501 interferon receptor JFNAR 2-1 
[H.sapiens]" 1.7 
AA132065 AF140225 hypothetical protein AF140225 1.7 
R59138 - ESTs 1.6 
AA056945 SLC25A14 "solute carrier family 25 (mitochondrial carrier, brain), member 14" 1.6 
H59114 FLJ20036 hypothetical protein FLJ20036 1.6 
AA570285 AGA aspartylglucosaminidase 1.6 
AA580371 NCKAP1 NCK-associated protein 1 1.5 
R19539 - ESTs 1.5 
AI014456 KIAA1495 KIAA1495 protein 1.5 
N25676 RAB6A "RAB6A, member RAS oncogene family" 1.5 
AI200858 - EST 1.4 
R99527 - ESTs 1.4 
AF226684 PREB prolactin regulatory element binding 1.4 
AA557551 AF093680 similar to mouse Glt3 or D. malanogaster transcription factor IIB 1.4 
AA601026 U2AF1RS1 
"U2 small nuclear ribonucleoprotein auxiliary factor, small subunit 
1" 1.4 
R95927 - ESTs 1.4 
R51859 - ESTs 1.4 
AA148685 - 
"ESTs, Weakly similar to JC5256 adipocyte transcription factor, 
AEBP1 [H.sapiens]" 1.4 
AI124066 - ESTs 1.3 
AW978447 DLEU2 "deleted in lymphocytic leukemia, 2" 1.3 
AI824983 BLu BLu protein 1.3 
N68447 - ESTs 1.3 
T71990 WBP2 WW domain binding protein 2 1.3 
AI041212 - ESTs 1.3 
AA568660 LOC51057 hypothetical protein 1.3 
U65785 ORP150 oxygen regulated protein (150kD) 1.3 
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AI139029 - ESTs 1.3 
AI094575 - EST 1.3 
AA995008 E2F3 E2F transcription factor 3 1.3 
BE502246 EDG4 
"endothelial differentiation, lysophosphatidic acid G-protein-
coupled receptor, 4" 1.3 
U17327 NOS1 nitric oxide synthase 1 (neuronal) 1.3 
    
genes underexpressed at 12hrs  
    
NM_001379 DNMT1 DNA (cytosine-5-)-methyltransferase 1 0.4 
AA233944 ZIRTL zinc/iron regulated transporter-like 0.6 
BE672508 - 
"Homo sapiens cDNA: FLJ21927 fis, clone HEP04178, highly 
similar to HSU90909 Human clone 23722 mRNA sequence" 0.6 
U80735 PAXIP1L PAX transcription activation domain interacting protein 1 like 0.6 
AA699810 RPL38 ribosomal protein L38 0.7 
AI184515 COX8 cytochrome c oxidase subunit VIII 0.7 
AA923451 KIAA1464 KIAA1464 protein 0.7 
BE538254 OSTF1 osteoclast stimulating factor 1 0.7 
H60560 - "Homo sapiens cDNA FLJ11562 fis, clone HEMBA1003197" 0.7 
BF111145 NSMAF neutral sphingomyelinase (N-SMase) activation associated factor 0.7 
H51180 FLJ20847 hypothetical protein FLJ20847 0.7 
NM_004482 GALNT3 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (GalNAc-T3) 0.7 
R99600 - 
"ESTs, Highly similar to A57291 cytokine inducible nuclear protein 
C193 [H.sapiens]" 0.7 
AI571293 E2-EPF ubiquitin carrier protein 0.7 
























Table 9. Genes overexpressed and underexpressed at 18hr time point 
 
genes overexpressed at 18hrs  
    




"ESTs, Weakly similar to S59501 interferon receptor JFNAR 2-1 
[H.sapiens]" 3.5 
AA575975 FDX1 ferredoxin 1 3.4 
AW027443 SEC3 Sec3-like 3.0 
AA570469 AP2A2 "adaptor-related protein complex 2, alpha 2 subunit" 3.0 
AA558494 MGC3279 hypothetical protein MGC3279 similar to collectins 2.7 
AA604681 LOC55924 hypothetical protein 2.6 
R61077 MGC4179 hypothetical protein MGC4179 2.5 
R60338 - "Homo sapiens cDNA FLJ14609 fis, clone NT2RP1000944" 2.4 
AA600235 NEK6 NIMA (never in mitosis gene a)-related kinase 6 2.4 
AA057313 MORF histone acetyltransferase 2.2 
AA548229 - "Homo sapiens cDNA: FLJ22446 fis, clone HRC09457" 2.2 
AA609970 CRHSP-24 calcium-regulated heat-stable protein (24kD) 2.1 
AA580371 NCKAP1 NCK-associated protein 1 2.1 
AI184207 - 
"ESTs, Highly similar to T46442 hypothetical protein 
DKFZp434F2427.1 [H.sapiens]" 2.1 
AA147461 - ESTs 2.0 
AA054341 FLJ10342 hypothetical protein FLJ10342 2.0 
N25676 RAB6A "RAB6A, member RAS oncogene family" 2.0 
R54386 - 
Homo sapiens mRNA; cDNA DKFZp586B211 (from clone 
DKFZp586B211) 1.9 
H59114 FLJ20036 hypothetical protein FLJ20036 1.9 
AA593835 FLJ20494 similar to mouse neuronal protein 15.6 1.9 
R56598 
TU12B1-
TY TU12B1-TY protein 1.9 
H39212 - "ESTs, Weakly similar to PN0099 son3 protein [H.sapiens]" 1.9 
AA601026 U2AF1RS1 
"U2 small nuclear ribonucleoprotein auxiliary factor, small subunit 
1" 1.8 
AI474618 RAD1 RAD1 (S. pombe) homolog 1.8 
AI538453 MYC v-myc avian myelocytomatosis viral oncogene homolog 1.8 
M78435 MLL2 myeloid/lymphoid or mixed-lineage leukemia 2 1.7 
AA021432 LOC51012 CGI-107 protein 1.7 
AA617796 HDAC5 histone deacetylase 5 1.7 
R18931 LOC51122 HSPC042 protein 1.7 
AA132065 AF140225 hypothetical protein AF140225 1.6 
AA628544 MGC2963 hypothetical protein MGC2963 1.6 
AA551124 - "Homo sapiens cDNA FLJ12825 fis, clone NT2RP2002800" 1.6 
R92205 - ESTs 1.6 
R09157 - ESTs 1.6 
AA834395 - ESTs 1.5 
BF185645 MRPL33 mitochondrial ribosomal protein L33 1.5 
R83160 - EST 1.5 
R95927 - ESTs 1.5 
R44078 MKLN1 "muskelin 1, intracellular mediator containing kelch motifs" 1.5 
AL442082 SLC13A3 
"solute carrier family 13 (sodium-dependent dicarboxylate 
transporter), member 3" 1.5 
 98
T55488 SLC21A6 "solute carrier family 21 (organic anion transporter), member 6" 1.4 
AI279943 - EST 1.4 
AI124066 - ESTs 1.4 
R51859 - ESTs 1.4 
X68830 IAPP islet amyloid polypeptide 1.4 
AA553499 PDCD6IP programmed cell death 6-interacting protein 1.4 
H80842 - ESTs 1.4 
R00224 - "Homo sapiens, clone IMAGE:3952677, mRNA, partial cds" 1.4 
AI014456 KIAA1495 KIAA1495 protein 1.4 
AA568660 LOC51057 hypothetical protein 1.4 
AI190439 SNRPC small nuclear ribonucleoprotein polypeptide C 1.4 
R38613 - ESTs 1.4 
BE622365 BCL7B B-cell CLL/lymphoma 7B 1.3 
N69207 - ESTs 1.3 
AA570285 AGA aspartylglucosaminidase 1.3 
AA557551 AF093680 similar to mouse Glt3 or D. malanogaster transcription factor IIB 1.3 
R96020 KIAA0416 KIAA0416 protein 1.3 
AI192520 - ESTs 1.3 
R52970 - ESTs 1.3 
AI440025 IL2RG 
"interleukin 2 receptor, gamma (severe combined 
immunodeficiency)" 1.3 
R94566 FLJ10989 hypothetical protein FLJ10989 1.3 
R19539 - ESTs 1.3 
R59777 ME3 "malic enzyme 3, NADP(+)-dependent, mitochondrial" 1.3 
AA043412 PPIC peptidylprolyl isomerase C (cyclophilin C) 1.3 
    
genes underexpressed at 18hrs  
    
AI571293 E2-EPF ubiquitin carrier protein 0.7 
BE893265 PFDN1 prefoldin 1 0.7 
BE543109 AP2M1 "adaptor-related protein complex 2, mu 1 subunit" 0.6 
BE694068 YWHAZ 
"tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide" 0.6 
AI911758 HLA-DRA "major histocompatibility complex, class II, DR alpha" 0.6 
BF339718 ACTB "actin, beta" 0.5 









3.0   NR4A family of transcription factors are upregulated in C1 mediated apoptosis 
 
Our microarray results show the upregulation of a number of transcripts at early time 
points including NR4A3 (table 2, table 4, table 5). We have validated our finding 
regarding NR4A3 transcript upregulation by real time PCR. We find as in previous 
studies using other drugs (Inuzuka et al., 2002; Shin et al., 2003; Smith et al., 2008; 
Wansa et al., 2003) that the NR4A3 transcript is transiently upregulated at time points 
1hr-4hr and then the transcript level diminishes (figure 10). We went ahead to 
characterize the impact on other members of the NR4A family of receptors and found 
that the NR4A1 transcript is also transiently and highly upregulated upon C1 treatment at 
early time points (1hr 2hr ) and diminishes by 12hrs (figure 11). NR4A1 transcript has 
also been shown in several cases to be transiently upregulated (Crawford et al., 1995; 
Williams and Lau, 1993; Woronicz et al., 1994). NR4A2 transcript was not found to be 
affected by C1 drug treatment (figure 12). 
More specifically, there is a seven fold upregulation of NR4A3 by 2 hrs after which it 
slowly recedes and by 8 hrs the transcript level is down to basal levels. In the case of 
NR4A1 there is a fourteen fold increase in transcript levels by one hour and it gradually 
decreases but even at 18 hrs it is more than two fold of its basal level. NR4A2 levels are 
slightly elevated at the 1hr and 2 hr time points by about one and a half fold but lower 



















Figure 10. Drug C1 transiently increases transcription of NR4A3 in MCF-7 cells: MCF-7 
cells were treated with C1 50ug/ml or C1 0ug/ml and RNA was harvested at indicated 
time points. NR4A3 gene expression analysis was performed by Q-RT-PCR. Results 
were normalized to GAPDH expression and converted to fold induction relative to 


















































Figure 11. Drug C1 transiently increases transcription of NR4A1 in MCF-7 cells: MCF-7 
cells were treated with C1 50ug/ml or C1 0ug/ml and RNA was harvested at indicated 
time points. NR4A1 gene expression analysis was performed by Q-RT-PCR. Results 
were normalized to GAPDH expression and converted to fold induction relative to 
















































Figure 12. Drug C1 does not affect transcription of NR4A2 in MCF-7 cells: MCF-7 cells 
were treated with C1 50ug/ml or C1 0ug/ml and RNA was harvested at indicated time 
points. NR4A2 gene expression analysis was performed by Q-RT-PCR. Results were 
normalized to GAPDH expression and converted to fold induction relative to untreated 

































4.0   Silencing the transcript of NR4A1 and NR4A3 impact apoptosis 
 
Since NR4A1 and NR4A3 transcripts are upregulated in response to drug C1 at early 
time points and as NR4A1 and NR4A3 are transcription factors we endeavoured to gauge 
the effect of silencing NR4A1 and NR4A3 in MCF-7 cells especially the cell death 
response to drug treatment 
 
4.1   NR4A1 and NR4A3 transcripts are effectively silenced by siRNA 
 
NR4A1 and NR4A3 were both effectually silenced at 24 hrs, 48hrs and 72hrs post 
transfection with the corresponding siRNAs in MCF-7 cells.  
NR4A1 silencing at 24, 48 and 72 hrs was to about 0.4 fold of the controls that had been 
silenced for a non targeting sequence (the negative control) (figure 13A). Upon treatment 
of the NR4A1 silenced cells with C1 50 μg/ml for 2 hrs we found that the increase in 
mRNA levels induced by the drug which led to about fourteen fold increase in transcript 
level of NR4A1 in the negative control was greatly quenched and the transcript was about 
four fold the level of the untreated negative control. However the silencing does not 
completely eleminate the increase in transcript upon C1 50µg/ml treatment. 
NR4A3 silencing at 24, 48 and 72 hrs was to 0.1 fold of the negative control (figure 
13B). Upon treatment of the NR4A3 silenced cells with C1 50 ug/ml for 2 hrs we found 
that the increase in mRNA levels induced by the drug which led to about seven fold 
increase in transcript level of NR4A3 in the negative control was greatly decreased and 























Figure 13. NR4A1 and NR4A3 transcripts can be effectively silenced in MCF-7 cells: 
Silencing of  (A) NR4A1 or (B) NR4A3 transcripts by siRNA: MCF-7 cells were 
transfected  with siRNA to NR4A3 or NR4A1 or nontargeting siRNA  according to 
manufacturer’s protocol and after 24, 48 and 72 hours were treated with C1 50 μg/ml or 0 
μg/ml for 2hrs and RNA was harvested and used for NR4A1, NR4A3 gene expression 
analysis which was performed by Q-RT-PCR. Results were normalized to GAPDH 
expression and converted to fold induction relative to untreated cells. Data represents the 




























































Figure 14. NR4A1 and NR4A3 transcripts can be simultaneously silenced by siRNA: 
MCF-7 cells were transfected  with siRNA to NR4A1 and NR4A3 simultaneously or 
with the nontargeting siRNA  according to manufacturer’s protocol and after 24, 48 and 
72 hours were treated with C1 50μg/ml or 0μg/ml for 2hrs and RNA was harvested and 
used for NR4A1 and NR4A3 gene expression analysis which was performed by Q-RT-
PCR. Results were normalized to GAPDH expression and converted to fold induction 
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We also attempted to silence both NR4A1 and NR4A3 transcripts simultaneously and 
found that while silencing of NR4A1 in the double silencing was similar in its trend to 
the single silencing, where the transcript level could be brought down effectively to 0.2 
fold of the negative control, upon C1 50µg/ml treatment for 2hrs the transcript level 
could be brought down to about five fold while negative control cells showed 
upregulation of about sixteen fold upon C1 50µg/ml treatment (figure 14). 
However silencing of NR4A3 is only about 0.8 fold in the double silencing (it had gone 
down to 0.1 fold in the single silencing experiments). And upon C1 50µg/ml treatment 
for 2 hrs the negative control shows about 7 fold upregulation of the NR4A3 transcript as 
expected (figure 10) while the double silenced cells show about 1.3 fold induction of 
NR4A3. The silencing of NR4A3 is not as effective in the double silencing as it had been 
in the single silencing where basal transcript levels had gone down to a tenth, and  
transcript level upon C1 treatment was 0.9 fold and on double silencing the 
corresponding levels are 0.8 and 1.3 fold. 
 
4.2   Silencing NR4A3 transcript affects cell viability upon low dose drug treatment 
 
Since NR4A3 transcript is upregulated in response to drug C1 at early time points and as 
NR4A3 is a transcription factor we endeavoured to gauge the effect of silencing NR4A3 
in MCF-7 cells especially the response to drug treatment. Our results show that silencing 
NR4A3 in MCF-7 cells  renders them less sensitive to low dose drug treatment.  
At 25µg/ml dosage of C1 the cells proliferate to 85% of control levels when they are 
transfected with the non targeting siRNA, however, upon silencing NR4A3 the cells 
 107
proliferate to 95%  of control levels as observed by MTT assay (figure 15). We find a 
similar trend at the lower dose of 12.5ug/ml where there is a 4% increase in viability 
when NR4A3 is silenced. However this difference in proliferation disappears at the 
higher drug dose of 50μg/ml and 100μg/ml. 
 
4.3   Silencing NR4A3 transcript affects BrdU assimilation upon low dose drug 
treatment 
 
Another way to analyze cell proliferation is the measurement of DNA synthesis as a 
marker for proliferation. To quantitate DNA synthesis bromodeoxyuridine is added to 
cells and its incorporation into DNA in place of the thymidine can be quantified. If the 
cell is proliferating it will take up more of the BrdU than if it is proliferating less and this 
difference can be determined. 
We went on to reconfirm our finding of the effect of silencing NR4A3 on cell viability by 
looking at the assimilation of BrdU upon drug treatment in cells that had been similarly 
transfected with non targeting siRNA or a siRNA to NR4A3. We again found a 
difference between BrdU assimilation in the NR4A3 silenced cells compared to the cells 
transfected with non targeting siRNA. The NR4A3 silenced cells assimilate13% more of 
BrdU than the corresponding non targeting siRNA transfected control cells at the 
25µg/ml dose of C1 and 18% more at the C1 12.5µg/ml dose (figure 16). And once again 
we find this effect disappearing at higher drug doses of 50µg/ml of C1 and 100µg/ml of 
C1. 
We therefore conclude NR4A3 behaves like a tumor suppressor and is required for the 
decrease in cell viability upon xenobiotic stress, and in its absence the cell is unable to 
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respond appropriately to the toxic effect of the drug at the lower concentrations. This 
impact dissipates when drug dose is higher when presumably many other factors or 
pathways may be involved and may supersede any consequence of NR4A3 silencing. 
NR4A3 has been implicated (along with NR4A1) as critical tumor suppressors of 
myeloid leukemogenesis where its abrogation causes symptoms resembling acute 
myeloid leukemia in mice  (Mullican et al., 2007). However, we find that in MCF-7 cell 
line silencing of NR4A3 alone itself has a impact on cellular response to drug treatment 
at low dosage of the drug.  
 
4.4   Silencing NR4A1 transcript affects cell viability upon C1 drug treatment  
 
Since silencing NR4A3 affected viability upon C1 drug treatment we went on to decipher 
the effect of silencing NR4A1 which is a member of the NR4A subfamily and whose 
levels also transiently increase upon C1 treatment and we found a much more 
pronounced effect on cell viability upon C1 treatment at all doses of the drug C1. More 
specifically, at C1 100µg/ml there is a 10% increase in viability when NR4A1 transcript 
is silenced relative to the non targeting control transfected cells treated similarly, at C1 
50µg/ml and 25µg/ml a 20% difference and at 12.5µg/ml a 10% increase in viability 
compared to the cells tranfected with the non targeting siRNA (figure 15).  
In the case of NR4A3 silencing the difference in viability was more modest, 4%, 10% at 
C1 12.5µg/ml and C1 25µg/ml and this difference disappeared at the C1 50µg/ml and 
100µg/ml doses. With silencing of the NR4A1 transcript the difference in viability is 
 109
perceived even at the high doses and the magnitude of difference in viability at the lower 
doses is considerably larger. 
This reflects the substantial role of NR4A1 in C1 mediated apoptosis in MCF-7 cells. 
Double silencing NR4A1 and NR4A3 showed a trend similar to what we identify from 
silencing NR4A1 alone (figure 15) presumably because the effect of silencing NR4A1 is 
overwhelming and the additive effect of silencing NR4A3 is not identifiable. It could also 
be attributed to the difference in efficiency of silencing the transcripts as silencing 
NR4A3 transcript alone was found to be more effectual and transcript levels of NR4A3 
were lower than when  double silencing was carried out (figure 13B, figure 14). 
 
4.5   Silencing the NR4A3 transcript affects VDAC1 translocation  
 
4.5.1 The coexpression neighbourhood of NR4A3 includes VDAC1  
 
As our results showed that NR4A3 is involved in C1 mediated apoptosis we strived to 
look for proteins that might be interacting with NR4A3 or involved in the downstream 
signal transduction cascade that NR4A3 is part of and are therefore functionally related to 
NR4A3. So we looked at the coexpression neighbourhood of NR4A3  and we found that 
there was a positive correlation between NR4A3 and, among other proteins, VDAC1, in 
two of the datasets (perou-breast, staunton-nci60) (Lee et al., 2004). VDAC1 is 
associated with the mitochondrial permeability transition pore (MPTP) (Cesura et al., 
2003) and is believed to be an important constituent of this pore which opens a path 
between the outer and inner mitochondrial membranes. VDAC1 was originally detected 
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in the outer mitochondrial membrane, where it mediates the translocation of various 
metabolites and other compounds in and out of the mitochondria (e.g. pyruvate, malate, 
ADP, ATP, etc). It has also been found to be an important player in the regulation of 
mitochondrial cytochrome c release in some forms of apoptosis by interacting with 
members of the Bcl-2 family of proteins (Shimizu et al., 1999). We pursued this hunch 
























































Figure 15. Silencing of NR4A3 or NR4A1 or both transcripts protects from drug 
mediated cell death to varying extents compared to cells transfected with control non 
targeting siRNA: MCF-7 cells were transfected with non targeting control siRNA or 
NR4A3 siRNA or NR4A1 siRNA or NR4A1 and NR4A3 siRNA, and after 24 hours 
were treated with C1 12.5, 25, 50, 100 µg/ml for 18 hrs and cell survival was assessed by 
MTT assay and expressed as percentage survival of untreated cells. Results are expressed 
as the means of eight (for siRNA to NR4A3 and non targeting control) or four (for 
siRNA to NR4A1 or NR4A1 and NR4A3) separate experiments, and comparisons were 
made using the two-tailed Student’s t test for sample with unequal variance ; bar denote 































Figure 16. Silencing NR4A3 transcript increases ability to proliferate as measured by 
BrdU incorporation upon low dose C1 treatment in MCF-7 cells: MCF-7 cells were 
transfected with non targeting siRNA or NR4A3 siRNA and 24 hrs post transfection were 
incubated with different concentrations of C1 for 18 hrs. The Cell Proliferation ELISA 
BrdU colorimetric assay kit from Roche was used to determine cell proliferation. Values 
are reported as the percentage of control absorbance, correcting for background 
absorbance. Results are expressed as the means of six separate experiments, and 
comparisons were made with two-tailed Student’s t test for sample with unequal 







4.5.2   VDAC1 protein levels and transcript levels upon C1 treatment 
 
We had earlier identified that VDAC1 protein levels increase in the mitochondrial 
fraction upon C1 treatment (figure 17A). We found a dose dependant increase in VDAC1 
protein levels upon C1 treatment in MCF-7 cells, data is shown for the 6hr, 12hr and 18hr 
time points and we find that as early as 6 hrs in the high dose 100µg/ml we see an 
increase in VDAC1 protein levels in the fraction enriched for mitochondrial proteins. By 
12 hrs the increase in VDAC1 protein levels is discernable in the 25µg/ml and the 
50µg/ml dosages as well and we see a similar trend at the 18 hr time point (figure 17A) 
The transcript of VDAC1 does not vary upon C1 treatment with time as all the way from 
30 mins to 18 hrs, the VDAC1 transcript level stays fairly stable (figure 18B) 
The total VDAC1 protein levels are also invariant (figure 18A), so we infer that VDAC1 
may be translocating from the plasma membrane where it has been postulated to be a 
NADH (-ferricyanide) reductase and is involved in transmembranous redox regulation 
(Baker et al., 2004; Elinder et al., 2005) . However we do not find any VDAC1 protein in 
the cytosolic fraction (which should include light membranes) possibly because it is too 
dilute a fraction (figure 17B). 
 
4.5.3   Silencing the NR4A3 transcript decreases VDAC1 translocation 
 
We have found that in the fraction enriched for mitochondrial proteins when NR4A3 is 
silenced the translocation of VDAC1 caused by C1 to the mitochondria is significantly 
blocked (Fig 19A). The experiment is done at the 12 hr time point post drug treatment 
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and in the controls which are transfected with non targeting siRNA there is a increase in 
the VDAC1 levels in the fraction enriched for mitochondrial proteins, the increase is dose 
dependant and the densitometry analysis shows that at 0μg/ml, 25μg/ml, 50μg/ml and 
100μg/ml dosage of C1 the percentage change in VDAC1 levels relative to GAPDH with 
the non targeting siRNA control cells is 100%, 230%, 300%,300% and with the NR4A3 
siRNA treated cells 24%, 60%, 140%, 180%. The relative levels of VDAC1 are much 
lower when NR4A3 is silenced, and even when 25μg/ml dose of C1 is used it is still 
lower than the basal levels, however there isn’t a complete repression of VDAC1 as with 
the higher doses the relative amounts of VDAC1 do increase above basal levels. 
Our results suggest that NR4A3 may be essential for VDAC1 translocation probably 
from the plasma membrane to the mitochondria upon drug treatment. We find that the 
decrease in VDAC1 translocation upon NR4A3 silencing corresponds to the effect of 
NR4A3 silencing on drug induced abrogation of cell death but only when the drug dosage 
is low. At higher drug doses we find that although VDAC1 levels are still low the effect 
on the proliferation of the cells is eliminated.  
At greater xenobiotic stress the effect of lower VDAC1 levels may be compensated for 
by other proteins in the MPTP (mitochondrial permeability transition pore) like other 
VDAC or ANT isoforms. It is now believed that while VDAC, ANT and cyclophilin D 
are important constituents of the MPTP, VDAC and ANT isoforms may be able to 
compensate for each other (Baines et al., 2007) and while VDAC1 may exert a specific 
role in C1 mediated inhibition of proliferation the deluge of signals accompanying higher 











Figure 17. VDAC1 protein levels increase in the fraction enriched for mitochondrial 
proteins upon C1 drug treatment in a dose and time dependent manner in MCF-7 cells: 
(A)  MCF-7 cells were treated with C1 drug at various doses for 6,12 or 18hrs and they 
were subjected to fractionation as described in materials and methods and the fraction 
enriched for mitochondrial proteins was immunoblotted for VDAC1, and GAPDH was 
used as loading controls. (B) MCF-7 cells were treated with C1 drug at various doses 
for12 hrs and they were subjected to fractionation as described in materials and methods 
and the fraction enriched for mitochondrial proteins and the cytosolic fraction was 
















































Figure 18. VDAC1 transcript levels and total protein levels are invariant upon C1 
treatment in MCF-7 cells: (A) MCF-7 cells were incubated with C1 0ug/ml for 1 hr or C1 
50ug/ml for various time points from 1 hr to18 hrs and the whole cell lysates were 
immunoblotted with anti VDAC1 antibody, GAPDH was used as loading control. (B) 
MCF-7 cells were treated with C1 50ug/ml and RNA was harvested at indicated time 
points. VDAC1 gene expression analysis was performed by Q-RT-PCR. Results were 
normalized to GAPDH expression and converted to fold induction relative untreated 
cells. Data represents the mean +/- SEM of three independent experiments.  
VDAC1 31kda 
GAPDH 37kDa 











































































Figure 19. Silencing NR4A3 transcript leads to decrease in VDAC1 levels in the fraction 
enriched for mitochondrial proteins including when treated by drug C1 in MCF-7 cells: 
(A)  MCF-7 cells were transfected with non targeting siRNA and NR4A3 siRNA and 
after 24hrs were incubated with drug C1 at different doses for 12hrs and cells were 
harvested and fractionated and the fraction enriched for mitochondrial proteins was 
immunoblotted for VDAC1. GAPDH is loading control. (B) Densitometry analyses of 



















4.6   Silencing NR4A3 does not affect PARP1 clevage, Bax translocation, AIF 
Translocation 
 
As described in section 1.9 PARP1 clevage is observed upon C1 treatment as early as 6 
hrs upon high dose treatment (100µg/ml of C1) and by 12 hrs we see PARP1 clevage at 
both the 50µg/ml and the 100µg/ml doses. As the silencing of NR4A3 has notable effects 
on cell proliferation and VDAC1 translocation we endeavoured to look for changes in 
PARP1 clevage upon C1 treatment. However, we find that there is no remarkable 
difference in PARP1 clevage upon NR4A3 silencing at the 12 hr time point (figure 20A).  
We also strived to look at the effect of silencing NR4A3 on other characteristic apoptotic 
features like the release of AIF from the mitochondria into the cytosol and the 
translocation of Bax from cytosol to mitochondria. We found that at 12 hrs when, as 
described in section 1.7 and 1.8 the translocation of AIF to the cytosol is noticeable at the 
50µg/ml and 100µg/ml doses of C1 and the translocation from the cytosol of Bax is also 
discernible, when NR4A3 is silenced, we do not observe any changes relative to the cells 
silenced with the non targeting control siRNA (figure 20B). 
 
4.7   Silencing NR4A3 does not affect jun levels 
 
Mice with null mutation in NR4A1 and NR4A3 have been described to show symptoms 
of acute myeloid leukemia including having low expression of c-Jun. As we have been 
able to silence NR4A3 and have been able to see a small but definite effect on cell 
survival due to the silencing of NR4A3 we went ahead to check the status of c-Jun and p-
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Jun in our system. The c-Jun antibody detects endogenous levels of total c-Jun protein, 
regardless of phosphorylation state and the p-Jun  (phospho-c-Jun) antibody detects 
endogenous levels of c-Jun only when activated by phosphorylation at Ser73. This 
antibody also recognizes JunD phosphorylated at Ser100. The transcriptional activity of 
c-Jun is regulated by phosphorylation at Ser63 and Ser73. 
We found an unequivocal increase in both the total Jun (c-Jun) and p-Jun at the two hour 
and the three hour time points at the C1 25ug/ml and C1 50ug/ml doses relative to control 
levels (which measures c-Jun levels in untreated cells) as shown in figure 21A. 
Upon silencing NR4A3 and treating the cells with C1 for 3 hrs, we do not see any 
difference between the protein levels of cells transfected with siRNA to NR4A3 and 
those transfected with siRNA to a non targeting control (figure 21B). So we conclude 
silencing NR4A3 alone does not impact upon Jun mediated signaling in MCF-7 cells 






















Figure 20. Silencing NR4A3 does not affect PARP1 cleavage, Bax and AIF translocation 
upon C1 treatment in MCF-7 cells: (A) MCF-7 cells were transfected with non targeting 
siRNA and NR4A3 siRNA and after 24hrs were incubated with drug C1 at 0, 25, 50 and 
100µg/ml doses for 12hrs and cells were harvested and the whole cell lysate was probed 
with PARP1 antibody. GAPDH is loading control. (B) MCF-7 cells were transfected with 
non targeting siRNA and NR4A3 siRNA and after 24hrs were incubated with drug C1 at 
different doses as above for 12hrs and cells were harvested and fractionated and the 
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Figure 21. c-Jun and p-Jun levels increase upon C1 treatment at specific doses and time 
points but are not regulated by NR4A3 transcript levels (A)  MCF-7 cells were incubated 
with C1 at 0, 25, 50 or 100µg/ml concentrations of C1 for 1, 2, 3, 4, 6, 12 or 18 hrs and 
the whole cell lysates were probed with anti c-Jun antibody or anti p-Jun antibody. 
GAPDH was used as loading control. (B) MCF-7 cells were transfected with non 
targeting siRNA and NR4A3 siRNA and after 24hrs were incubated with drug C1 at 0, 
25, 50 and 100µg/ml doses for 3hrs and cells were harvested and the whole cell lysate 

















































PART V   DISCUSSION 
 
1.   Microarray technology and the uncovering of drug induced signal transduction 
pathways 
 
There has been a great deal of work to try and understand how classical drugs effect 
cancer cells and cause them to undergo apoptosis or other related cell death mechanism 
like senescence or autophagy or necrapoptosis. The central idea is of course that once we 
can decipher the molecular mechanism of drug action we will be able to make more 
suitable judgements regarding suitability of the drug for a particular patient whose 
genetic profile is appropriately deciphered. Conventional drugs and the pathways they 
influence have been the subject of immense interest to biologists, and there has been 
some headway in understanding the signal transduction pathways these drugs initiate that 
ultimately results in apoptosis or related mechanism of cell death. The receptors that 
come into play and the mediators of the signal transduction pathway are now being 
unveiled and these new revealations about drug induced signal transduction show ways to 
counter resistance to the drugs. Much research has gone into understanding how drugs 
effect apoptosis through p53-dependent stimulation of the Fas/FasL system (Muller et al., 
1997; Srivastava et al., 1999). This in turn reflects why many drugs may not be 
successful in cases where p53 is non functional, guiding the use of these drugs in a 
functional p53 patient cohort. Many studies have focused on finding targets to improve 
drug sensitivity, which can be restored using another drug in combination that, say, 
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allows for inhibition of Akt levels (Wang et al., 2008)(which are important for 
proliferation) thus allowing for designing alternate strategies to combat cancer. 
 
High throughput technologies like microarray analysis are particularly suited to a global 
search for strategies to understand the pathways a drug may invoke, the knowledge of 
which may be used to improve drug potency. Also, microarray technology can benefit 
cancer therapy by allowing the unraveling of the molecular events following drug 
treatment that may be of consequence in therapy. Microarray data is increasingly being 
used to validate new drugs and understand the gene expression profile changes triggered 
by new drugs in development in pre clinical studies (Podar et al., 2006; Takeda et al., 
2007). Gene expression and gene ontology analysis have shown the upregulation of many 
proapoptoic gene ontology groups and a downregulation of genes controlling mitosis, and 
thus microarray experiments serve to further delineate drug targeted molecular pathways. 
 
Our approach was similarly to look for the early events caused by drug C1 that result in 
apoptosis in HL60 and M14 cells to understand the signal transduction initiated by this 
drug. Previous work has shown this drug to work through early production of reactive 
oxygen species (ROS) (unpublished data) and subsequent activation of the apoptotic 
machinery including a drop in transmembrane potential, activation of caspases and 
translocation of cytochrome c (Pervaiz et al., 1999). Our microarray data analysis results 
show that a large number of genes including many transcription factors are upregulated in 
the early time points and we could validate by real time PCR the upregulation of the 
NR4A3 transcript in response to drug C1 in both HL60 cells (data not shown) and MCF-
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7 cells. We have gone on to show the importance of orphan nuclear receptors of the 
NR4A family in this system, both NR4A1 and NR4A3 are important players here.  
 
However we do note that the fold change in gene expression observed in this study is in a 
narrow range and less than four fold alteration of gene expression are observed. We 
attribute this to the inherent issues of in house printed arrays. Also, although we printed 
around 18,000 different spots each representing a unique gene, after the data is filtered 
for valid values we are only left with 5968 genes for further analysis. Nevertheless, we 
have been able to identify many potential players in the C1 mediated apoptotic pathway. 
Many of these genes are known to be associated with regulation of cell cycle through 
interactions with transcription factors, while others are known to be regulated by stress 
related factors. 
Of the genes upregulated in the 30mins 1hr and 2 hr time points we find many 
transcription factors involved in impeding the cell cycle like NR4A3, ELF3, SMAD5 and 
YY1, we find phosphatases and kinases important in regulating the cessation of the cell 
cycle like DUSP4, NEK6, STK24. We also spot potential/known tumor suppressors like 
TLE1, TGFBR3, and constituents of known checkpoint complexes like RAD1, TP53BP1. 
Also involved are genes known to be expressed in response to genotoxic stress like 
STAG1, CRH, and enzymes important in detoxification of cells from harmful metabolites 
like ALDH7A1, GSTM1 
Downregulation of genes whose products result in stimulation of the cell cycle and 
transcription factors associated with cell proliferation are seen as anticipated. 
Downregulation of coactivators of nuclear receptors like SMAP, kinases like PKC iota,  
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downregulation of transcription factors important in progression of the cell cycle like 
E2F5 and E2F3, and  downregulation of NCKAP1 gene transcript which leads to 
apoptosis in neuronal cells by mechanisms not fully understood are all reflecting the 
many pronged signal transduction pathways initiated by C1. 
 
2.   Drug C1 is a potent inducer of apoptosis 
 
Drug C1 is a purified photoproduct of the chromophore merocyanine 540 which is one of 
the drugs featured in the Developmental Therapeutics Program of the national cancer 
institute (NCI) where NCI uses in vivo animal tumor models to screen for compounds for 
potential antitumor activity and the in vivo screening data shows its efficacy in treatment 
of some models of leukemia. However it has been shown that merocyanine 540 is even 
more potent upon preactivation where the compound is exposed to light prior to its use in 
biological systems (Pervaiz, 2001). Preactivated merocyanine 540 (pMC540) has been 
shown to be specific to leukemia and lymphoma cell lines like Daudi (Burkitt’s 
lymphoma), HL60 (leukemia), histiocytic lymphoma (U-937) tumor cells and its 
cytotoxicity towards normal human cells (mononuclear cells) is very low (survival of 
85% for normal cells and 20% for tumor cells) (Gulliya and Pervaiz, 1989) (Gulliya et 
al., 1990). Previous work on pMC540 treatment of MCF-7  breast adenocarcinoma cells 
in vitro and on MCF-7 cells grown as solid tumors with estrogen stimulation and 
implanted in athymic mice has shown the in vivo effectiveness of pMC540 in 
suppression of breast tumors (Gulliya et al., 1994).  
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Drug C1 has been shown to have potent antitumor effects on HL60 leukemia and M14 
melanoma cells (Pervaiz et al., 1999).  
We show here that the drug C1 shows effective inhibition of cell survival and causes the 
morphological  changes of cell shrinkage, loss of contact with other nearby cells due to 
rounding up and disadherence from the substrate. It also leads to release of apoptogenic 
factors cytochrome c, AIF from the motochondria and a concomitant loss in 
transmembrane potential (ψm) due to outer mitochondrial membrane permeabilization. 
We were initially surprised by the lack of DNA degradation upon drug treatment in 24 
hrs as the cells look visibly rounded and we see release of cytochrome c and AIF from 
the mitochondria to the cytosol. However as in MCF-7 cells there is a deficiency of 
caspase 3 they are known to undergo aberrent DNA fragmentation (Kagawa et al., 2001) 
and it is known that AIF, endonuclease G, Omi/HtrA2, which are other factors important 
in caspase independent cell death may take over the caspase 3 function including of 
cleavage of PARP1 (Broker et al., 2005; Wang et al., 2002; Yu et al., 2002), it may 
explain the initial lack of DNA fragmentation though there is conspicuous PARP1 
clevage.  
We also show the effect to be more specific to cancer cells and relatively less toxic to 
‘normal’ cells, and make a case for its inclusion among compounds that need to be 






3.   NR4A family members are important in drug response 
 
3.1   NR4A transcripts are short lived  
 
Both NR4A3 and NR4A1 have been seen by us and others to be transcripts that are 
transiently upregulated (Bandoh et al., 1995; Bandoh et al., 1997; Cheng et al., 1997; 
Hazel et al., 1991; Martinez-Gonzalez et al., 2003; Maruyama et al., 1997; Ohkubo et al., 
2000; Pirih et al., 2003; Rius et al., 2006; Shin et al., 2003; Smith et al., 2008; Wansa et 
al., 2003; Williams and Lau, 1993). Many RNA transcripts of inducible proteins are 
known to turn over rapidly – this ensures a rapid response to extracellular stimuli. Genes 
with unstable transcripts are known to encode proteins that play important regulatory 
roles. Unstable transcripts tend to possess AU-rich motifs in the 3’-UTRs like those of 
multiple inflammatory mediators, including tumor necrosis factor, colony-stimulating 
factor and IL-1 (Garneau et al., 2007). Also, multiple immediate response genes, cell-
cycle genes, transcription factors and oncogenes are found to encode short-lived 
transcripts containing ARE (AU-rich elements) (Bevilacqua et al., 2003). These motifs 
facilitate the rapid turnover of these transcripts and help to prevent inappropriate 
accumulation of the regulatory molecules that they encode. These ARE sequences have 
been identified in NR4A3 (Ohkura et al., 1994) and may be the cause of its instability. 
We find that both NR4A1 and NR4A3 are important in C1 mediated apoptosis and 
NR4A2 is not which is a common theme in many studies pointing to a redundancy in 
function between these two receptors (Cheng et al., 1997; Mullican et al., 2007; 
Thompson and Winoto, 2008). Thus the transient nature of the NR4A transcripts may be 
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an essential feature for their mode of action as an overexpression of NR4A1 or NR4A3 is 
deleterious (Cheng et al., 1997), and further studies need to be done to ascertain if more 
stable forms of NR4A1 or NR4A3 could sensitize cells to drug mediated apoptosis. 
 
3.2   NR4A transcript levels modulate response to drugs 
 
We also find that regulation of the levels of NR4A transcripts may be important in the 
apoptotic response of a cell to an agonist. Our work shows that in MCF-7 cells silencing 
the NR4A3 transcript prevents the complete response of the cells to the drug, and 
silencing NR4A1 has an even greater impact on diminishing the apoptotic effect of the 
drug. We conclude that NR4A1 and NR4A3 are important players in C1 mediated 
apoptosis and a decrease in their levels prevents the cells from being able to respond to an 
apoptoic stimulus and thus NR4A1 and NR4A3 behave like tumor supressors. Similar 
results were inferred from double knockout mice that were deficient in NR4A1 and 
NR4A3 and showed symptoms of acute myeloid leukemia (Mullican et al., 2007) and this 
work showed abrogation of both renders mice to have abnormal myeloid cell 
proliferation. Abrogation of only one of the genes did not have any conspicuous effect. 
We find however that silencing NR4A3 alone itself has a small effect at low drug dosage.  
We went on to confirm our findings regarding the NR4A3 role in cell survival post drug 
treatment with the bromodeoxyuridine incorporation test which looks at the ability of the 
cell to take up nucleotides and perform DNA synthesis with or without treatment with the 
drug, and we found that NR4A3 does indeed impact the ability of the MCF-7 cells to 
accomplish DNA synthesis. 
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There are several reports indicating NR4A1’s role in modulating the response of cells to 
drugs. However, in the fibroblastic cell line HEK293 where NR4A1 was overexpressed it 
has been shown to be antiapoptotic in response to etoposide and camptothecin which are 
DNA damaging agents and thapsigargin which causes endoplasmic reticulum stress (de 
Leseleuc and Denis, 2006). Many studies have found NR4A1 to be overexpressed in 
several types of cancer indicating its overexpression may provide for a proliferative 
advantage for the cancer (Cho et al., 2007; de Leseleuc and Denis, 2006). 
Among reports showing the proapoptotic role of NR4A1 is a recent study in vitamin k 
induced apoptosis in ovarian cancer cells where apoptosis was found to be associated 
with NR4A1 levels and silencing NR4A1 transcript prevented apoptosis (Sibayama-
Imazu et al., 2008), the authors also demonstrate that in the cell line less susceptible to 
vitamin k induced apoptosis there is no NR4A1 in the nuclei and mitochondria, thus 
correlating NR4A1 levels and response to cell death stimuli (de Leseleuc and Denis, 
2006). Using new developmental drugs derived from 3,3’ diindolylmethane (DIM) that 
are NR4A1 agonists it has again been shown that NR4A1 levels are important in 
apoptotic response and lowering NR4A1 levels by siRNA to NR4A1 greatly diminishes 
the apoptotic response including  decrease in PARP1 clevage of human colon carcinoma 
RKO cell line cells (Cho et al., 2007). 
NR4A1 has been shown to  translocate from the nucleus to the mitochondria upon 
various drug induced apoptotic stimuli (Li et al., 2000; Sibayama-Imazu et al., 2008),  
interact with Bcl-2 in the mitochondria and causes a conformational change in Bcl-2 
making it proapoptotic. Bcl-2 was found to be necessary for the apoptotic effect of 
NR4A1 and its mitochondrial targeting as cells bereft of Bcl-2 either endogeneously or 
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by silencing of Bcl-2 through siRNA showed aberrant localization of NR4A1 and had 
limited apoptotic response (Lin et al., 2004). Also, it was found that the transactivation by 
NR4A1 which was seen with growth stimuli like EGF and caused reporter gene 
transcription was not induced by apoptotic stimuli like TPA, ionophore or etoposide. 
Thus its transactivation activity has been found to be unimportant for the apoptotic 
function (Li et al., 2000). A recent report has also shown that silencing of NR4A1 and 
NR4A2 in melanocytes impairs their ability to repair DNA lesions following uv 
irradiation again indicating NR4A1 levels to be important in response to DNA damage 
(Smith et al., 2008). Another recent report suggests that in thymocytes both NR4A1 and 
NR4A3 translocate to the mitochondria and associate with Bcl-2 and impact apoptosis 
(Thompson and Winoto, 2008). 
Our results for the role of NR4A1 are in line with the reports showing the proapoptotic 
attributes of NR4A1 as we also find a substantial diminution of cell death response upon 
silencing NR4A1. 
 
The consequence of NR4A3 levels in drug mediated apoptosis has been described in a 
study analyzing gene expression outcomes of patients receiving chemotherapy for diffuse 
large B-cell lymphoma and the authors have found that patients with higher expression of 
NR4A3 (among other genes) tend to have better prognosis (Shipp et al., 2002).  
It s role in apoptosis has come into the fore in a recent publication where in mice lacking 
both NR4A3 and NR4A1 it was shown that NR4A1 and NR4A3 together behave like 
tumor suppressors and their abrogation leads to tumorigenesis (Mullican et al., 2007). 
Also, in thymocytes, engagement of the TCR correlates with strong induction of NR4A1 
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and NR4A3 and correlates with apoptotic response. NR4A1 and NR4A3 have both been 
found to translocate to the mitochondria, a process that was found to be inhibitable by 
leptomycin B which is a nuclear export inhibitor. The apoptotic response was also found 
to be highly diminished in the prescence of leptomycin B indicating the significance of 
NR4A1 and NR4A3 translocation from nucleus to mitochondria for the apoptotic 
phenotype (Thompson and Winoto, 2008).  
 
While the (Mullican et al., 2007) and (Thompson and Winoto, 2008) papers reflect the 
growing perception that NR4A3 is important in apoptosis, its role in drug mediated 
apoptosis has not been characterized so far and our work provides a glimpse of its role in 
drug mediated apoptosis. 
 
3.3   Interaction with mitochondrial proteins may channel apoptotic response of 
NR4A family members 
 
Both NR4A1 and NR4A3 being nuclear receptors and transcription activators are 
implicated in the response of cells to drugs but the mechanism of their action is not fully 
understood yet. NR4A1 has been shown to translocate to the mitochondria and to interact 
with Bcl-2 causing its BH3 domain to be exposed (Lin et al., 2004) and a recent report 
shows that NR4A1 and NR4A3 both translocate to the mitochondria and interact with 
Bcl-2 making it proapoptotic in T cell development (Thompson and Winoto, 2008). 
NR4A1 and NR4A2 can heterodimerise with RXR while NR4A3 does not (Zetterstrom et 
al., 1996), it is believed that RXR provides the nuclear export signal required for 
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NR4A1’s translocation to the mitochondria. And since leptomycinB has been shown to 
be able to block the interaction of NR4A1 and NR4A3 with Bcl-2 the authors (Thompson 
and Winoto, 2008) convincingly conclude that NR4A3 also translocates to the 
mitochondria.  
Our results show that NR4A3 may have an impact on VDAC1 which is a mitochondrial 
outer membrane protein and is known to interact with Bcl-2 family proteins (Rostovtseva 
et al., 2004; Shimizu et al., 1999; Zheng et al., 2004). We suggest that the effect of 
silencing NR4A3 that we observe on cell proliferation upon drug treatment may be 
brought about by its effect on VDAC1 levels in the mitochondria whether this effect is 
passed on by Bcl-2 family members first interacting with NR4A3 and then affecting 
VDAC1 levels or if it is a direct interaction between NR4A3 and VDAC1 is yet to be 
ascertained. 
We find that the increase in VDAC1 protein levels in the mitochondrial is not 
accompanied by an increase in its transcript or an increase in the total amount of the 
VDAC1 protein of the cell. This reflects that VDAC1 is probably translocating from the 
plasma membrane to the mitochondria upon apoptotic stimuli. However we have not 
been able to find any VDAC1 protein in the cytosolic fraction (which includes the light 
membrane fraction associated with the plasma membrane). We account for this by 
assuming that the cytosolic fraction does not have enough concentration of the protein 
(that is, it is too dilute) for the detection of VDAC1.  
VDAC1 prescence has previously been detected in bovine brain astrocytes in the 
detergent resistant membrane fraction (Dermietzel et al., 1994), and have been found in 
caveoli which are plasma membrane organelles with low solubility in Triton X-100 or in 
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detergent insoluble glycolipid enriched complexes (DIGs) using sucrose gradient 
fractions and the VDAC1 protein has been found in the same fractions as the caveolae 
(Bathori et al., 1999), or in plasma membrane enriched fractions of human Namalwa  ρ0 
cells (which lack a functional mitochondrial respiratory chain), (Baker et al., 2004), and 
to the plasma membrane lipid raft fractions and not the caveolae fractions in mouse 
neuroblastoma cells (Bahamonde et al., 2003).  
As the location of the VDAC1 outside of the mitochondria varies in terms of the specific 
location and may be a function of the cell type, we have to ascertain its localization in 
MCF-7 and examine its translocation to the mitochondria upon C1 treatment to be able to 















PART VI   CONCLUSIONS 
 
We have been able to characterize the apoptotic effects of the drug C1 in the breast 
adenocarcinoma cell line MCF-7. C1 is an interesting investigational drug because of its 
ability to cause classical apoptosis in several cell lines including M14 melanoma cells 
and human leukemia HL60 cells and now we have further discerned its apoptotic 
characteristics in MCF-7 cells. We have been able to compare its effects on cancer cell 
lines relative to the corresponding ‘normal’ cells and have found it to be more specific to 
cancer cells. 
 
We had embarked on a quest to identify the genes important in C1 drug mediated 
apoptotic response and we have brought it to consummation with the identification of the 
orphan nuclear receptors NR4A1 and NR4A3 as being significant in the signal 
transduction pathway initiated by C1. We have also been able to show the downstream 
impact of the NR4A family members on the cell death response and can thus assign a 
physiological role for these nuclear receptors in MCF-7 cells treated with drug C1.  
 
We also propose a mechanism of action for the nuclear receptors – our observation that 
silencing NR4A3 reduces the quantity of VDAC1 protein in the fraction enriched for 
mitochondrial proteins suggests the involvement of VDAC1 (which has previously been 
associated with proapoptotic characteristics) in NR4A3 mediated response to cell death 
trigger by drug C1. 
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